A genetic approach toward defining the role of Factor X in development and coagulation by Tai, Shing Jen
A Genetic Approach toward Defining the Role of Factor X
in Development and Coagulation
A Thesis
Submitted to the Faculty
of
Drexel University
by
Shing Jen Tai
in partial fulfillment of the
requirements for the degree
of
Doctor of Philosophy
July 2005
© Copyright 2005
Shing Jen Tai.  All Rights Reserved.
ii
Dedications
The work presented here is dedicated to the author’s parents, Mr. and Mrs. Tai.
iii
Acknowledgments
The author wishes to acknowledge her mentor, Dr. Katherine High for her
advice, encouragement, support, and guidance.  She also wishes to
acknowledge the members of her committee, Dr. Fred Allen, Dr. Patricia
Labosky, Dr. Peter Lelkes, and Dr. Margaret Wheatley for their time and
support.  Furthermore, she likes to thank Dr. Roland Herzog, Dr. Valder Arruda,
Dr. Jeff Golden, F. Parker Hudson, and kirk Chu for their advice and assistance
in the study.  Finally, the author thanks her parents for their support and
understanding.
iv
Table of Contents
LIST OF TABLES................................................................................................ ix
LIST OF ILLUSTRATIONS...................................................................................x
ABSTRACT ........................................................................................................ xii
1. INTRODUCTION ........................................................................................... 1
1. GENERATION AND CHARACTERIZATION OF FX KNOCK-OUT MICE...... 9  
      2.1 Introduction.............................................................................................. 9
      2.2 Materials and Methods .......................................................................... 12
            2.2.1 Isolation of Murine FX Genomic DNA........................................... 12
            2.2.2 Construction of the FX Socket-Targeting Vector .......................... 12
            2.2.3 Electroporation and Selection of Neo-Resistant ES Cell Clones .. 15
            2.2.4 Homologous Recombination between the FX Socket Construct
and FX Locus............................................................................... 16
            2.2.5 Isolation of ES Cell DNA and Mouse Genomic DNA .................... 17
            2.2.6 PCR Analysis on ES Cell DNA and Mouse Genomic DNA........... 18
            2.2.7 Southern Blot Analysis on ES Cell DNA and Mouse Genomic
DNA ............................................................................................. 19
            2.2.8 Generation of FX-Deficient Mice................................................... 19
            2.2.9 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) on
Total RNA Isolated from Liver Tissues......................................... 20
            2.2.10 Northern Blot Analysis on Total RNA.......................................... 20
            2.2.11 Western Blot Analysis on Plasma and Extracts Isolated from
Liver Tissues .............................................................................. 21
            2.2.12 Activated Partial Thromboplastin Time (aPTT) and
Prothrombin Time (PT) FX Assays ............................................. 22
            2.2.13 Timed Mating Experiment........................................................... 23
v            2.2.14 Immunohistochemical Staining for PECAM-1 and ICAM-2......... 23
      2.3 Results .................................................................................................. 24
            2.3.1 Construction of the FX Socket-Targeting Vector .......................... 24
            2.3.2 Targeted Disruption of FX Exon 8 ................................................ 25
            2.3.3 PCR Results................................................................................. 25
            2.3.4 Southern Blot Results................................................................... 27
            2.3.5 Targeting Frequency .................................................................... 29
            2.3.6 Production of FX Knock-Out Mice ................................................ 29
            2.3.7 Phenotypic Characterization of FX Knock-Out Neonates ............. 30
2.3.8 Genotype Analysis of the Offspring from Heterozygous FX(+/-)
          Intercross..................................................................................... 32
            2.3.9 Evaluation of Embryonic Lethality and Phenotype of FX
Knock-Out Mice ........................................................................... 33
            2.3.10 Detection of a Partial Transcript in FX Knock-Out Mice.............. 34
            2.3.11 Absence of FX Antigen in FX(-/-) Neonates ............................... 36
            2.3.12 Coagulation Activities of Plasma from FX(-/-) Newborn Mice ..... 38
            2.3.13 Immuno-Staining of E13.5 Embryo Sections for PECAM-1
and ICAM-2 ................................................................................ 39
      2.4 Discussion ............................................................................................. 40
vi
1. GENERATION AND CHARACTERIZATION OF FX KNOCK-IN MICE ....... 45
      3.1 Introduction............................................................................................ 45
      3.2 Materials and Methods .......................................................................... 49
            3.2.1 Construction of the FX Plug-Targeting Vector .............................. 49
            3.2.2 Electroporation and Selection of HAT-Resistant ES Cell Clones . 52
            3.2.3 Isolation of ES Cell DNA and Mouse Genomic DNA .................... 52
            3.2.4 PCR Analyses on ES Cell DNA and Mouse Genomic DNA ......... 53
            3.2.5 Southern Blot Analysis on ES Cell DNA and Mouse Genomic
DNA ............................................................................................. 53
            3.2.6 DNA Sequencing to Confirm Substitution of TCC for CCC in
FX Exon 8 .................................................................................... 54
            3.2.7 Generation of Homozygous FX-Friuli [FX(F/F)] Mice.................... 54
            3.2.8 Western Blot Analysis of Plasma.................................................. 54
            3.2.9 Generation of FX(-/F) Mice........................................................... 55
            3.2.10 Activated Partial Thromboplastin Time (aPTT) and
Prothrombin Time (PT) FX Assays ............................................. 56
            3.2.11 Genotypic Analysis of Offspring from Mating of FX(-/F) Mice..... 56
            3.2.12 Phenotypic Analysis of Embryos Resulting from FX(-/F)
Mothers ...................................................................................... 57
            3.2.13 Histological Analysis of FX-deficient Mice .................................. 57
      3.3 Results .................................................................................................. 58
            3.3.1 Homologous Recombination between the FX Plug-Targeting
                     Vector and FX Knock-Out Locus .................................................. 58
vii
            3.3.2 PCR Results................................................................................. 59
            3.3.3 Southern Blot Results................................................................... 62
            3.3.4 Targeting Frequency in the Knock-In Experiment......................... 62
            3.3.5 DNA Sequencing Results ............................................................. 63
            3.3.6 Production of Homozygous FX(F/F) Mice..................................... 64
            3.3.7 Levels of FX Antigen in FX(F/F) Mice........................................... 66
            3.3.8 Levels of FX Activity in FX(F/F) Mice............................................ 66
            3.3.9 Generation of FX(-/F) Mice........................................................... 67
            3.3.10 Levels of FX Activity in FX(-/F) Mice........................................... 68
            3.3.11 Genotypic Analysis of the Offspring from FX(-/F) Intercross ...... 69
            3.3.12 Phenotypic Analysis of Embryos from FX(-/F) Mothers .............. 70
            3.3.13 Histological Analysis of FX-Deficient Mice.................................. 73
      3.4 Discussion ............................................................................................. 77
1. FX EXPRESSION DURING DEVELOPMENT............................................. 89
      4.1 Introduction............................................................................................ 89
      4.2 Materials and Methods .......................................................................... 91
            4.2.1 Timed Mating of Heterozygous FX(+/-) Mice ................................ 91
            4.2.2 Synthesis of FX Riboprobes ......................................................... 91
            4.2.3 Whole-Mount In Situ Hybridization (E9 to E12.5) ......................... 92
            4.2.4 In Situ Hybridization of Paraffin-Embedded Embryo Tissue
Sections (E13.5 to E15.5) ............................................................ 93
            4.2.5 Immunohistochemical Staining for FX Antigen ............................. 95
      4.3 Results .................................................................................................. 96
             4.3.1 Whole-Mount In Situ Hybridization (E9 to E12.5) ........................ 96
viii
             4.3.2 In Situ Hybridization of Paraffin-Embedded Embryo Tissue
Sections (E13.5 to E15.5)........................................................... 99
             4.3.3 Immunohistochemical Staining for FX Antigen .......................... 102
      4.4 Discussion ........................................................................................... 105
1. SUMMARY AND FUTURE DIRECTIONS.................................................. 110
LIST OF REFERENCES ................................................................................. 114
VITA ................................................................................................................ 121
ix
List of Tables
1. Mouse Models of Thrombosis and Hemostasis ............................................ 2
1. Genotype Distribution among Offspring from Heterozygous FX(+/-)
Intercross.................................................................................................... 33
1. Genotype Distribution among Offspring of Heterozygous FX(+/-) Parents . 34
1. Coagulation Times in Seconds of FX(+/+), FX(+/-), and FX(-/-) Newborn
Plasma........................................................................................................ 39
1. A List of Some Naturally Occurring Human FX Variants with Mutations in
Exon 8 ........................................................................................................ 47
1. Genotype Distribution among Offspring from Heterozygous FX(+/F)
Intercross.................................................................................................... 65
1. FX Coagulation Activity in FX(+/+) , FX(+/F) and FX(F/F) Adult Mice......... 67
1. Genotype Distribution in Offspring Resulting from Cross of FX(F/F)
Females and FX(+/-) Males ........................................................................ 68
1. FX Coagulation Activity in FX(-/F) Mice and Age-Matched Wild-Type Adult
Mice............................................................................................................ 69
1. Genotype Distribution among Offspring from FX(-/F) Intercross................. 70
1. Comparison of FX(+/-) Intercross and FX(+/F) Intercross........................... 79
1. Comparison of FX(+/-) Intercross and FX(-/F) Intercross ........................... 83
xList of Illustrations
1. Illustration of the Coagulation Cascade ......................................................... 5
1. Illustration of the Prothrombinase Complex ................................................... 6
1. Construction of the 5’ and 3’ FX Targeting Arms ......................................... 14
1. Construction of the FX Socket-Targeting Vector.......................................... 15
1. Targeted Disruption of FX Gene .................................................................. 17
1. PCR Analysis of ES Cell DNA...................................................................... 26
1. PCR Analysis of Mouse Genomic DNA ....................................................... 27
1. Southern Blot Analysis of ES Cell DNA ....................................................... 28
1. Southern Blot Analysis of Genomic DNA ..................................................... 28
1. Phenotypic Comparison of FX(+/+) and FX(-/-) Neonates ........................... 31
1. Kaplan-Meier Survival Curve of Homozygous FX Knock-Out Mice.............. 31
1. Subcutaneous Bleeding in a FX(-/-) Mouse ................................................. 32
1. RT-PCR Analysis of FX Transcript from FX(+/+) and FX(-/-) Neonates....... 35
1. Northern Blot Analysis of Total RNA from FX(+/+), FX(+/-) and FX(-/-)
Livers ........................................................................................................... 36
1. Western Blot Analysis of Plasma from FX(+/+), FX(+/-) and FX(-/-) Mice .... 37
1. Western Blot Analysis of Cell Lysates from FX(+/+), FX(+/-) and FX(-/-)
Livers ........................................................................................................... 38
1. Immuno-Staining of E13.5 Embryo Sections for PECAM-1 and ICAM-2 ..... 40
1. Construction of the FX Plug-Targeting Vector.............................................. 51
1. Targeted Knock-In of FX-Friuli ..................................................................... 58
1. PCR and Restriction Enzyme Digest (BanI)................................................. 60
1. PCR Analysis to Differentiate FX(+/F), FX(F/F), and FX(-/F) Mice .............. 61
xi
1. Southern Blot Analysis of DNA from HAT-Resistant ES Clones .................. 62
1. Sequencing Analysis of PCR Products ........................................................ 64
1. Western Blot Analysis of Plasma ................................................................. 66
1. Examination of E10.5, E11.5 and E12.5 FX-Deficient Littermates from
     FX(-/F) Mothers ............................................................................................ 72
1. Examination of E13.5 FX-Deficient Littermates from a FX (+/-) Mother ....... 73
1. Histologtical Analysis of the Heart Tissues from FX-Deficient Mice ............. 75
1. Co-Localization of Iron Deposits and Fibrosis.............................................. 76
1. Histological Analysis of the Spleen Tissues from FX-Deficient Mice............ 77
1. Whole-Mount In Situ Hybridization of E9 Embryos ...................................... 97
1. Whole-Mount In Situ Hybridization of an E10.5 Embryo .............................. 97
1. Whole-Mount In Situ Hybridization of E11.5 Embryos ................................. 98
1. Whole-Mount In Situ Hybridization of E12.5 Embryos ................................. 98
1. In Situ Hybridization of E13.5 Wild-Type Paraffin-Embedded Embryo
Sections ..................................................................................................... 100
35. In Situ Hybridization of E14.5 Wild-Type Paraffin-Embedded Embryo
      Sections..................................................................................................... 101
36. In Situ Hybridization of E15.5 Wild-Type Paraffin-Embedded Embryo
      Sections..................................................................................................... 102
37. FX Expression in E12.5 Embryos.............................................................. 103
38. FX Expression in E14.5 Embryos.............................................................. 104
39. FX Expression in E15.5 Embryos.............................................................. 105
xii
Abstract
A Genetic Approach toward Defining the Role of Factor X
in Development and Coagulation
Shing Jen Tai
Katherine A. High, MD.
Activated Factor X (FX) is a vitamin K-dependent serine protease that plays a
crucial role in blood coagulation by converting prothrombin to thrombin.  There
are no humans with complete deficiency of FX.   The overall objective of this
study is to investigate the role of FX in development and coagulation by
generating FX-deficient mouse models and determining the embryonic pattern
of FX expression.   First, a FX knock-out mouse model was engineered by
eliminating FX exon 8 and its 3’ flanking sequence; this resulted in embryonic or
perinatal lethality in FX -/- mice.  Approximately 50% of FX -/- embryos died
between days 10-12 of development.  Fatal bleeding in the remaining FX(-/-)
animals occurred soon after birth.  The cause of embryonic lethality remains
unclear.  Next, a viable mouse model of FX deficiency was generated.  These
mice expressed a FX variant with normal antigen levels but a low level of
activity (4-9% in humans carrying the analogous defect, Pro343→Ser, termed FX
Friuli). Homozygous mice had FX coagulation activity of ~5.5% of normal, which
was sufficient to rescue both embryonic and perinatal lethality.  To generate
mice with even lower FX activity, FX(F/F) and FX(+/-) mice were crossed.  Their
offspring, FX(-/F) mice, indeed had even lower FX activity (1-3% of normal) and
nonetheless also showed complete rescue of embryonic and perinatal lethality.
Therefore, while complete absence of FX is incompatible with murine and
xiii
human survival, minimum FX activity as low as 1% demonstrates sufficiency in
rescue of FX knockout mice from lethality.  FX(-/F) mice provided an
opportunity to assess the relative contributions of maternal and embryonic FX
as well as FX activity and antigen to embryonic survival.   FX(-/F) mice also
facilitated investigation into a developmental role of FX by allowing for
examination of FX(-/-) embryos born to mothers with minimal levels of FX
activity.   Furthermore, FX expression in multiple embryonic tissues was
detected by in situ hybridization and immunostaining.  Combined, these results
represent an initial investigation into defining the role of FX in development.
11. Introduction
A powerful genetic tool to unveil important biological functions of a gene product
is the generation of an animal model lacking a functional copy of the respective
gene. Generation and detailed characterization of mouse models with
deficiencies in various hemostasis-related components have enabled
investigators to gain unparalleled insights into their roles not only in maintaining
a critical balance in hemostasis, but also in supporting embryonic development
and survival.  Murine models for deficiencies of various clotting factors and
hemostatic components can be approximately divided into two groups. Thus far,
it has been learned that mice with deficiencies in factor VII (FVII), factor VIII
(FVIII), factor IX (FIX), factor XI (FXI), fibrinogen, platelets, protein C (PC), or
protein Z (PZ) completed embryogenesis and exhibited variable neonatal
phenotypes ranging from nearly normal prognosis to hemostatic defects of
various severities (Table 1).1-9 While absence of any of the above mentioned
hemostasis-related components did not impede embryonic development,
deficiencies in factor V (FV), prothrombin (FII), tissue factor (TF), tissue factor
pathway inhibitor (TFPI), or thrombomodulin (TM) invariably resulted in
embryonic lethality of variable penetrance (Table 1).10-17   Table 1 below
summarizes the mouse models of thrombosis and hemostasis.
2Table 1. Mouse models of thrombosis and hemostasis (kindly provided by Dr. R.
Camire, University of Pennsylvania).
The murine and human factor X (FX) genes are similar in several
aspects.  As it is in humans, murine FX is located immediately downstream of
the FVII gene in a head to tail orientation.18,19   Murine FX (20-kb) and human
FX (26-kb) have an identical exon-intron organization; each gene is comprised
of 8 exons and 7 introns; furthermore, with the exceptions of exon 6 and exon 8,
each exon in murine FX is identical in length to the analogous exon in human
FX.20-22   Striking similarities were also noted in the relationship between
domain structure of the FX protein and specific exons of the FX gene.  For both
murine and human FX genes, exon 1 encodes the signal peptide; exon 2, the
propeptide and the Gla domain; exon 3, a short stack of aromatic amino acids;
3exons 4 and 5, the EGF-1 (epidermal growth factor –1) and EGF-2 (epidermal
growth factor –2) domains, respectively; exon 6, the activation peptide; and
exons 7 and 8, the catalytic domain.  Moreover, the organization of gene to
structural domain observed in murine and human FX is conserved by other
vitamin-K dependent clotting factors including FVII, FIX, and PC.22-25   The
murine FX cDNA is 1.4-kb in length; it encodes a precusor protein of 481 amino
acid residues with a molecular weight of approximately 54-kDa.26,27
 Based on sequence and structural homology with human FX protein, it
is likely that murine FX undergoes similarly complex post-translational
modifications before secretion.26,28-30   The essential modifications undergone
by human FX precursor protein include proteolytic removal of the 40-amino acid
pre-pro leader sequence (also evident in mouse FX precursor), vitamin K-
dependent γ-carboxylation of the first 11 glutamic acid residues in the Gla
domain, β-hydroxylation of aspartic acid residue 63, and removal of a specific
tripeptide (Arg 140-Lys-Arg 142) to generate a 59-kDa FX zymogen, consisting
of a heavy and light chain linked by a disulfide bond.26,31-34
Activation of both murine and human FX is accomplished by cleavage of
a specific Arg-Ile bond in the heavy chain, resulting in the removal of the heavily
glycosylated 49-amino acid and 52-amino acid activation peptides,
respectively.26,35 As serine proteases, murine and human FX contain a catalytic
triad (His 233/236, Asp279/282, and Ser376/379) respectively in the active
site.26,36   The amino acid sequence of mouse FX is over 70% conserved with
4that of human FX; the highest conservation (>80%) is found in the catalytic
domain.26
Blood coagulation FX is a vitamin K-dependent, two-chain plasma
protein that occupies a pivotal role in the coagulation cascade (Figure 1).
Under physiological conditions and in the presence of calcium and on a
phospholipid membrane surface, activation of FX to FXa, a serine protease of
the prothrombinase complex (Figure 2), is initiated following vascular injury.
Activation of FX to FXa is achieved by the Factor VIIa/Tissue Factor (FVIIa/TF)
complex in the extrinsic pathway and maintained by the Factor IXa/Factor VIIIa
(FIXa/FVIIIa) complex in the intrinsic pathway (Figure 1).35   Activation of FX by
either complex involves a cleavage of the same specific arginine-isoleucine
bond found near the amino-terminal end of the heavy chain of FX.26
5Figure 1. Illustration of the coagulation cascade (kindly provided by Dr. F. Khazi,
Children’s Hospital of Philadelphia)
6Figure 2. Illustration of the Prothrombinase complex (Kindly provided by Dr. R.
Camire).
In association with its activated nonproteolytic cofactor, factor Va (FVa),
activated FXa assembles on phospholipid membrane surfaces in the presence
of Ca2+ to convert prothrombin to thrombin by cleavage of two peptide bonds
(Figure 2).37,38   FXa is the only known physiological enzyme that catalyzes the
conversion of prothrombin (FII) to thrombin (FIIa).  In addition to its function of
generating thrombin required for fibrin clot formation and platelet activation, FXa
can also catalyze the activation of FV, FVII, FVIII, and protein C in vitro.39-42   To
maintain hemostasis, the procoagulant activities of FXa are counter-balanced
by its inhibitors.  Some plasma protease inhibitors of FXa activity include
antithrombin III (ATIII), α1 antitrypsin, and α2-macroglobulin.43-45   Furthermore,
7binding of tissue factor pathway inhibitor (TFPI) to FXa results in an inhibition of
the procoagulant activity of the FVIIa/TF complex.46
Several lines of evidence suggest that FX may have functions other than
hemostasis.  For example, in contrast to the closely related vitamin-K
dependent proteins FVII and FIX, expressed only in the liver, FX in adult
humans is also expressed in the stomach, lungs, skeletal muscle, ovary, testis,
and other tissues.47   In addition to its defined role in blood coagulation, FX/FXa
has been shown to elicit a wide range of biological responses both in vitro and
in vivo.48-54   These include stimulation of mitogenic activity in cultured rat aortic
smooth muscle cells, induction of cytokine production and expression of
adhesion molecules by human umbilical vein endothelial cells, up-regulation of
transcription factor, egr-1, in a keratinocyte cell line, and others.48,49,53   It is
important to note that for some FX/FXa induced responses, catalytic activity of
FXa is required, but for others, it is not required.48-54   In light of these findings,
an interesting investigation will be to determine whether a catalytically active
FXa is required for embryonic survival.  Additional evidence suggesting a non-
hemostatic role for FX during development includes expression of mouse FX
transcript as early as E7.5 prior to the formation of a functional circulatory
system.55   Given these findings, it is not unreasonable to hypothesize that FX,
beyond its critically defined role in blood coagulation, may exert other biological
influences that determine embryonic survival.
8In this study, the overall objective is to investigate the role of FX in
development and coagulation by generating and characterizing FX-deficient
mouse models and by determining the embryonic pattern of FX expression.
92. Generation and characterization of FX knock-out mice
2.1  Introduction
Over the years, a number of hemostasis-related knock-out mouse models have
been generated and characterized.  Some of the mouse models showed an
interesting phenomenon of variable embryonic lethality and postnatal mortality.
For example, as noted earlier, both FV and prothrombin (FII) deficiencies
resulted in partial embryonic loss and perinatal lethality.10-12   Given that FVa is
the cofactor of FXa in the prothrombinase complex, and prothrombin (FII) is the
substrate of FXa, the expectation here is that FX is likely to play a crucial role in
both embryonic and postnatal survival.  If true, this may reflect both
coagulation-dependent and coagulation-independent functions of FX.
As a matter of fact, no humans with complete deficiency of FX have been
reported.  Instead, all of the described mutations are either missense mutations
or compound heterozygotes with a deletion or stop codon on one allele and a
missense mutation on the other, suggesting that complete deficiency of FX is
incompatible with life.  Since it is likely that homozygous deletion of even a
single exon of FX would result in lethality, it seems prudent to generate a FX
knock-out mouse model using a plug-and-socket targeting strategy. This
strategy enables repeated modification or rescue of a disrupted locus, if
necessary.56
The plug-and-socket targeting strategy provides several advantages that
are critical to the overall design of the study presented here.  First, this strategy
enables targeted disruption of any specific locus, using an appropriately
10
designed socket construct.  A socket construct consisting of a selectable
marker Neo (neomycin resistance gene) and a partial HPRT (hypoxanthine
phosphoribosyl transferase) sequence is introduced into an HPRT-negative
murine ES (embryonic stem) cell line.  Upon homologous recombination, the
socket vector targets a specific region of a gene for replacement with a
Neo/ΔHPRT cassette. This targeted disruption of a gene effectively abolishes
the function of its gene product.  Thus, any effect resulting from complete
absence of a gene product can be accordingly investigated.  Second, this
strategy also facilitates repeated modification (or rescue) of a specific locus
previously disrupted by a socket vector.  This particular feature of the strategy is
highly desirable in the event that complete deficiency of a gene product is
lethal, precluding further use of such a mouse model.  In the rescue experiment,
the second “plug“ construct supplying the portion of HPRT sequence missing in
the socket vector is introduced into the ES cell line previously targeted by the
socket vector.  Upon homologous recombination, the Neo gene is eliminated by
restoration of a further modified gene sequence, and the full-length HPRT
sequence is reconstituted for positive selection of ES cells by growth on HAT
(hypoxanthine aminopterine thymidine) medium. The requirement for
reconstitution of the HPRT sequence is predicted to increase the percent of
correctly targeted clones identified after the second targeting event
(unpublished observation made by Dr. O. Smithies).  The use of the plug-and-
socket constructs affords an additional advantage.  Expression of the gene of
interest is driven under the control of the endogenous promoter, a particularly
11
desirable feature in the case of a gene like FX, which is expressed in a variety
of tissues, and in which the cause of the lethality in humans is still unclear.47
This added advantage ensures that the expression of any variant FX gene will
parallel that of the wild-type gene in both levels and sites of FX expression.
  The choice of specific FX sequences to disrupt in the FX coding region was
based on several considerations.  First, since it was uncertain what level of FX
expression would be required to rescue lethality, should lethality also occur in a
mouse model of complete FX deficiency, a region of the FX gene that encodes
variants with a range of FX activities and FX antigen levels was targeted for
disruption.  Since nearly half of the reported patients with FX deficiency have
mutations in exon 8, deletion of the exon 8 sequences would afford a wide
range of activity and antigen levels for “knock-in” or rescue.  Mutations
described for the human FX gene can be found on
http://www.med.unc.edu/isth/mutations-databases/Factor_X.htm.  Second,
since exon 8 encodes the last two residues (Asp279/282 and Ser376/379) of the
catalytic triad, one can potentially generate a FX variant (with complete
absence of activity but normal antigen levels) by making a substitution at either
of these residues (in fact, such a substitution has been described in a patient
heterozygous for a FX mutation, termed FX Stockton).57   Any influence on
embryonic survival of a catalytically inactive FXa molecule can then be
assessed.
In this chapter, the objectives are 1) to generate a FX knock-out mouse
model with deletion of exon 8 and its 3’ flanking sequence using the plug-and-
12
socket targeting strategy, 2) to characterize FX knock-out mice with respect to
the role of FX in coagulation and development.
2.2  Materials and methods
2.2.1  Isolation of murine FX genomic DNA
Designed from sequences in exon 8 of the murine FX cDNA sequence, the
forward primer (5'-GCCGAGTCCACACTGATGACA-3') and reverse primer (5'-
CCCTGTCAATCCACTT-3') PCR-amplified a 350-bp fragment from 129/SvJ
mouse genomic DNA (Stratagene, La Jolla, CA).26   After DNA sequencing to
confirm the identity of the fragment, the PCR-amplified mouse FX exon 8
sequence was used as a probe to screen a bacterial artificial chromosome
(BAC) library derived from HindIII, partially digested ES 129/SvJ DNA.  Two
BAC clones were found to hybridize with the 350-bp exon 8 probe; one of these
was further analyzed by restriction enzyme digest, field inversion gel
electrophoresis (FIGE), and Southern blot hybridization with the same PCR-
amplified probe as described above.  Subsequently, a 7-kb NheI digested
fragment was recovered.  PCR analysis and DNA sequencing of the isolated
fragment indicated that it contains exons 6, 7, and 8, the intervening introns,
and the flanking region downstream of exon 8.  Once the identity of the
recovered fragment was confirmed as the 3' portion of the murine FX gene, it
provided a basis for the design and construction of the FX socket vector.
2.2.2  Construction of the FX socket-targeting vector
The 7-kb NheI FX fragment was first cloned into a pCI vector (Promega,
Madison, WI); this resulted in a 11-kb plasmid vector (pCI-mFX-3’) (Figure 3A).
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To generate the 2.8-kb 5’ FX targeting arm, the BamHI and SphI digested
fragment from pCI-mFX-3’ was cloned into a pCI vector.  The resulting plasmid
vector is called pCI-5’ arm (Figures 3B and 4B).  To generate the 1.6-kb 3’ FX
targeting arm, the EcoRI and NheI digested fragment also from the pCI-mFX-3’
vector was ligated into a pCI vector at the EcoRI and XbaI sites.  The resulting
plasmid vector is called pCI-3’ arm (Figures 3C and 4A).
Engineered in the pPD20 plasmid vector (provided by Dr. Randy
Thresher, UNC Chapel Hill), the final FX socket construct (pPD20-mFX socket)
consists of 5' and 3' homologous sequences flanking a functional Neo gene and
a partially deleted, non-functional HPRT minigene (Figure 4C).  The 2.8-kb 5'
FX-targeting arm cloned into the NotI site in the pPD20 plasmid vector included
exon 6, intron 6, exon 7, and part of intron 7 of the murine FX gene (Figure 4C).
The 1.6-kb 3' FX-targeting arm cloned into the SalI site in the vector contained
sequence downstream of the putative polyadenylation signal (ATTAAA) and the
overlapping termination codon (TAA) of the FX gene.  The whole targeting
construct spanned about 16.2-kb and was linearized with SacII at the 5'
terminus of the 5' targeting arm (Figure 4C) before it was introduced into
E14TG2a HPRT-deficient ES cells (provided by Dr. Maeda).
14
Figure 3. Construction of the 5’ and 3’ FX targeting arms.  Shown in (A) is the
pCI-mFX-3’ vector containing the 7-kb NheI FX insert.  Shown in (B) is the pCI-5’ arm
vector containing the 2.8-kb 5’ targeting arm.  Shown in (C) is the pCI-3’ arm vector
containing the 1.6-kb 3’ targeting arm.
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Figure 4.  Construction of the FX socket-targeting vector.  Shown in (A) is the pCI-
3’ arm containing the 1.6-kb 3’ targeting arm. Shown in (B) is the pCI-5’ arm containing
the 2.8-kb 5’ targeting arm.  Shown in (C) is the final FX socket-targeting vector
(pPD20-mFX socket) before linearization and electroporation.
2.2.3  Electroporation and selection of Neo-resistant ES cell clones
HPRT-deficient murine ES cells (E14TG2a) were grown on irradiated murine
embryonic fibroblast feeder layers (MEFs) in HEPES buffered (10 mM)
Dulbecco's modified Eagle's medium (DMEM), supplemented with 15% fetal
calf serum (FCS), 0.1 mM non-essential amino acids, 2 mM L-glutamine, 0.1
mM β-mercaptoethanol, 1000 U/ml leukemia inhibitory factor (LIF), and 50
16
µg/ml of Gentamycin.58   The electroporation of ES cells was performed as
follows:  the murine E14TG2a cells (2-5 x 107 ES cells) were electroporated
(800V, 3µF) with 100 µg of SacII linearized FX socket-targeting vector (Figure
4C) for ~1 sec at room temperature.  Twenty-four hours after electroporation,
transfected ES cells seeded on Neo-resistant feeder layers were plated in G418
selection medium (300 µg/ml).  Individual transfected clones that survived the
G418 selection for 7-10 days were isolated and expanded in 96-well and 24-
well plates to obtain DNA for further analyses by PCR and Southern
hybridization before blastocyst injection.
2.2.4  Homologous recombination between the FX socket construct and
FX locus
Following homologous recombination between the FX socket construct (Figure
5A) and FX locus (Figure 5B) in the HPRT-negative ES cell line (E14TG2a),
exon 8 encoding the catalytic domain of the FX protein is deleted and replaced
with a functional Neo gene and a partially deleted, non-functional 3’ HPRT
sequence (Figure 5C).
17
Figure 5. Targeted disruption of FX gene. (A) FX knock-out (socket) construct
consists of a 2.8 kb 5’ and 1.6 kb 3’ homologous regions flanking a functional Neo
gene and a partially deleted HPRT minigene. The relevant EcoRV sites are indicated.
(B) The 3’ end of the wild-type FX locus shows exons 6, 7, and 8, introns and the
downstream flanking region. The darkened bar below exons 6 and 7 indicates the
position of the probe used in Southern blot analysis.  Relevant EcoRV sites are also
shown.  The distance between the two adjacent EcoRV sites in the wild-type FX locus
is approximately 4.7-kb (C) After homologous recombination between the FX socket
construct (A) and FX locus (B), exon 8 is replaced with the Neo gene and HPRT
minigene (C). The resulting distance between the two adjacent EcoRV in the FX knock-
out locus is now approximately 7.6-kb. The little arrows (under the 3’ arm) indicate the
location of a primer pair used in PCR analysis.  Presence of a 2.2-kb PCR amplification
product from the 3’ end of the FX knock-out locus indicates correct recombination at
the 3’ site.
2.2.5  Isolation of ES cell DNA and mouse genomic DNA
To analyze G418-resistant E14TG2a ES cell clones for presence of a FX
knock-out allele, DNA was isolated using the Easy DNA Kit (Invitrogen,
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Carlsbad, CA).  Both quantity and quality of the purified ES cell DNA were
adequate for subsequent PCR and Southern blot analyses.  For neonates,
genomic DNA was isolated from liver tissues of the sacrificed pups using the
same kit.  For adult mice (4 weeks-old), genomic DNA was extracted from blood
samples collected from the retro-orbital plexus into heparin-containing micro-
capillaries and subsequently purified using the QIAamp DNA Blood Mini Kit
(Qiagen, Valencia, CA).
2.2.6  PCR analysis on ES cell DNA and mouse genomic DNA
To demonstrate correct homologous recombination in E14TG2a cells between
the FX locus and the introduced FX socket construct at the 3' targeting arm, two
primers as indicated in Figure 5C (a forward primer 5'-
CCTTTGGGCGGATTGTTGTT-3' annealing to a sequence at the 3' terminus of
ΔHPRT minigene and a reverse primer 5'-
CATAAAGCCTTGCCCCGATAGATA-3' annealing to a sequence downstream
from the 1.6-kb FX homologous region) were used to PCR-amplify a 2.2-kb
fragment from the purified ES cell DNA. Presence of a 2.2-kb PCR amplification
product allowed rapid identification of those ES cell clones potentially containing
the FX exon 8-deleted allele.  This PCR reaction and a second PCR reaction to
amplify a 350-bp fragment from exon 8 (previously used to screen the BAC
library) were used in separate PCR reactions to differentiate FX(+/+), FX(+/-),
and FX(-/-) mice.
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2.2.7  Southern blot analysis on ES cell DNA and mouse genomic DNA
DNA from G418-resistant E14TG2a cell clones (identified by PCR to have been
correctly targeted by the electroporated FX socket-targeting construct at the 3'
homologous region), and DNA obtained from mice of heterozygous FX(+/-)
cross were subjected to further analysis by Southern hybridization to ensure
correct targeting at the FX 5' homologous region.  Both ES cell DNA and mouse
genomic DNA were digested with EcoRV, separated by electrophoresis on a
0.7% agarose gel, transferred onto Hybond-N+ positively charged nylon
membrane (Amersham Life Science, Arlington Heights, IL), fixed by alkali
treatment, and hybridized with a [32P-α]dCTP labeled probe in a standard
Southern hybridization.  Corresponding to the 5’ targeting arm of the FX socket-
targeting construct (Figures 5B and C), the probe was radio-labeled by [32P-
α]dCTP in a random primer annealing reaction (Random primer labeling kit,
Stratagene, La Jolla, CA) and purified from non-incorporated nucleotides using
G-50 Sephadex columns (Roche, Indianapolis, IN).
2.2.8  Generation of FX-deficient mice
The correctly targeted FX(+/-) E14TG2a cell clones were expanded for
production of chimeric mice performed by the Transgenic & Chimerice Mouse
Facility of the University of Pennsylvania.  One correctly targeted and expanded
FX(+/-) cell clone was micro-injected into C57/BL6 blastocysts, and implanted
into the uterine horns of pseudo-pregnant mice.  Chimeric males were mated
with wild-type C57/BL6 females to generate heterozygous FX (+/-) offspring,
which were intercrossed to obtain homozygous FX(-/-) knock-out mice.
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2.2.9  Reverse transcriptase-polymerase chain reaction (RT-PCR) on total
RNA isolated from liver tissues
Total RNA was isolated from livers of FX(+/+) and  FX(-/-) newborn mice using
Trizol reagent (GIBCO/BRL), and reverse transcribed into first-strand cDNA
using oligo(dT) primers (SuperScript Preamplification System, GIBCO/BRL).
Following the cDNA synthesis, two pairs of primers designed from FX cDNA
sequence 5' to exon 8 sequence (first pair: forward 5'-
AGCCCGGTGCAACTCAGC-3' and reverse 5'-TTCCCGGCCACCCACAAT-3';
second pair: forward 5'-TGCGCCAGCGGTTACTTC-3' and reverse 5-
TCGCCTGGCCTGATGGA-3') were used in separate PCR reactions to amplify
a 705-bp fragment (from exons 1 to 6) and a 390-bp fragment (from exons 5 to
7), respectively.  To PCR-amplify FX exon 8 from cDNA, the two primers
yielding the 350-bp amplification product (as described above) were used.  In a
control reaction, two additional primers (forward 5'-
CCTTCCTGTGCATGGAGTCCT-3' and reverse 5'-
GGAGCAATGATCTTGATCTTC-3') were used to amplify a 202-bp β-actin
cDNA sequence.
2.2.10  Northern blot analysis on total RNA
For Northern blot analysis, total RNA (20 µg) isolated from liver tissues of
neonates was electrophoresed on a 1% agarose gel under denaturing
conditions (2.2M formaldehyde), transferred onto a Hybond-N+ positively
charged nylon membrane, fixed by UV cross-linking, and hybridized with a
denatured FX cDNA fragment (705-bp) corresponding to exons 1-6.  The 705-
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bp FX cDNA fragment was amplified by RT-PCR and labeled with [32P-α]dCTP
as described above.  Subsequently, the same blot was stripped and probed
with a 202-b β-actin cDNA probe.
2.2.11  Western blot analysis on plasma and extracts isolated from liver
tissues
To detect FX protein in circulation, plasma samples were obtained from
FX(+/+), FX(+/-), and FX(-/-) neonates and from FX(+/+) and FX(+/-) adult mice.
Blood samples from neonates were collected and combined with one-tenth
volume of 3.8% sodium citrate in Eppendorf tubes; blood samples from adult
mice were drawn into heparin-containing micro-capillaries and transferred into
Eppendorf tubes.   Collected samples were immediately centrifuged at 9000
rpm for 10 minutes at 4°C to obtain plasma.  Furthermore, to show absence of
FX protein in liver extracts isolated from FX(-/-) pups, protein samples
precipitated from phenol-ethanol supernatants (obtained during isolation of total
RNA using GIBCO/BRL reagents) were also analyzed by Western blotting.
Both plasma samples (1:20 dilution) and protein samples 10 ng from liver
tissues were separated by electrophoresis in 10% SDS/12% Tris-HCL
polyacrylamide gels (Bio-Rad, Hercules, CA) under denaturing conditions, and
transferred onto Hybond ECL nitrocellulose membranes (Amersham Pharmacia
Biotech, Piscataway, NJ).  After blocking, FX antigen from plasma was
immunodetected with a horseradish-peroxidase conjugated rabbit anti-human
FX polyclonal antibody (1:300 dilution) (Cedarlane, Ontario, Canada).  FX
antigen from protein samples derived from liver extracts was immunodetected
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by an affinity-purified sheep anti-human FX polyclonal antibody (1:250 dilution)
(Cedarlane, Ontario, Canada), and a horseradish-peroxidase conjugated rabbit
anti-sheep immunoglobulin  (1:1000 dilution) (Dako, Carpiteria, CA).  Both
primary antibodies raised against human FX antigen were previously shown to
cross-react strongly with mouse FX protein (results not shown).  In both cases,
FX protein complex was then detected by applying chemiluminescence
reagents (Amersham Life Science, Piscataway, NJ).
2.2.12  Activated partial thromboplastin time (aPTT) and prothrombin time
(PT) FX assays
Blood collected from neonates and adult mice (4 to 6 weeks-old) was combined
with one-tenth volume of 3.8% sodium citrate and centrifuged as described
above to obtain plasma for measurement of FX coagulation activities by aPTT
(activated partial thromboplastin time) and PT (prothrombin time) assays.  To
measure FX coagulation activity by aPTT, 50 µl of plasma sample diluted (1:40)
in imidazole buffer (Hedwin, Baltimore, MD) was mixed with 50 µl of human FX-
deficient plasma (Biomerieux, Durham, NC) and 50 µl of aPTT reagent
(Biomerieux); the mixture was incubated at 37° C for 3 minutes before the
addition of 50 µl of 25 mM CaCl2 to initiate clot formation.  To measure FX
coagulation activity by PT, 50µl of plasma sample diluted (1:80) in imidazole
buffer was combined with 50 µl of human FX-deficient plasma, and incubated at
37° C for 3 minutes before the addition of 100 µl pre-warmed thromboplastin
reagent (Biomerieux).  Time elapsed in seconds before each clot formation was
determined by a fibrometer (Fibrosystem; BBL, Cockeysville, MD).  Specific
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dilution for each clotting assay was determined to maximize differences in
clotting times between the wild-type and heterozygous plasma.  In both clotting
assays, standard curves were generated based on values derived from pooled
normal mouse plasma.
2.2.13  Timed mating experiment
Timed mating of heterozygous FX(+/-) mice was set up.  FX-null embryos along
with their wild-type and heterozygous littermates were examined at different
time points during development.  After gross examination, genotype of each
embryo was determined from DNA extracted from the yolk sac.
2.2.14  Immunohistochemical staining for PECAM-1 and ICAM-2
To conduct immunohistochemical staining for PECAM-1 (platelet endothelial
cell adhesion molecules) and ICAM-2 (intercellular adhesion molecule-2), E13.5
embryos (FX-null embryos and their wild-type littermates) were harvested, fixed
in 4% paraformaldehyde at 4°C overnight, and processed for paraffin-
embedded sagittal sections (0.5 µm).  Following deparaffinization and re-
hydration, tissue sections were incubated with 10 µg/ml primary antibody, either
rat anti-mouse CD31(PECAM-1) or rat anti-mouse CD102 (ICAM-2)
(PharMingen, San Jose, CA).  Thereafter, sections were incubated with 5 µg/ml
mouse adsorbed, biotinylated rabbit anti-rat IgG (Vector Laboratories,
Burlingame, CA).  Vectastain ABC-AP kit (Vector laboratories) containing
alkaline phosphatase was used to amplify the complex formed between primary
and secondary antibodies.  Alkaline phosphatase activity on tissue sections was
then visualized with addition of Vector Blue (Vector Laboratories).  Negative
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control included omission of either rat anti-mouse CD31 or rat anti-mouse
CD102 in the experimental procedure.
2.3  Results
2.3.1  Construction of the FX socket-targeting vector
With the expectation that a deletion of murine FX would result in lethality, which
would then require rescue to produce a viable FX-deficient mouse model, we
chose to use the “plug-and-socket” targeting strategy originally described by
Detloff and colleagues.56   Screening of a 129/SvJ strain mouse genomic DNA
library with a 350-bp PCR-amplified mouse FX exon 8-specific probe identified
two BAC clones, each containing the 3' portion of the murine FX gene. Further
investigation of one isolated BAC clone by restriction enzyme digests, gel
electrophoresis, and Southern blotting yielded a 7-kb NheI digested fragment,
which (by PCR analysis) contained exons 6, 7, and 8, the intervening introns,
and the 3' flanking sequence of the murine FX gene (data not shown).
Sequencing analysis of the same fragment confirmed PCR results (data not
shown).  The 7-kb FX fragment with the exclusion of exon 8 and the
polyadenylation signal sequence (based on considerations discussed earlier)
was used for the construction of the 5' and 3' targeting arms. The final 16.2-kb
FX socket-targeting vector was comprised of a 2.8-kb 5' and a 1.6-kb 3' FX
homologous sequences flanking a functional Neo gene and a partially deleted,
non-functional HPRT gene (ΔHPRT) (Figures 4C and 5A).  The 2.8-kb 5'
targeting arm contained exon 6, intron 6, exon 7, and part of intron 7 and the
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1.6-kb 3' targeting arm contained genomic sequence downstream of the FX
stop codon and its overlapping polyadenylation signal sequence.
2.3.2  Targeted disruption of FX exon 8
FX socket construct designed to delete exon 8 and its 3’ flanking sequence was
electroporated into HPRT-deficient murine ES cells (E14TG2a) as described
above.  Homologous recombination between FX locus (Figure 5B) and the FX
knock-out vector (Figure 5A) resulted in targeted disruption of the FX gene by
replacing exon 8 encoding the catalytic domain of the serine protease with a
Neo and ΔHPRT cassette (Figure 5C).  This disruption effectively inactivates FX
function by completely abolishing the catalytic activity of the protein.  Following
transfection and selection in G418 medium, 192 G418-resistant ES clones were
isolated and analyzed for correct targeting by PCR.
2.3.3  PCR results
To identify correctly targeted Neo-resistant ES clones, DNA was first analyzed
by PCR using two specific primers as indicated in Figure 5C.  In this PCR
analysis, DNA from the correctly targeted ES clones yielded a 2.2-kb PCR
amplification product from the 3' end of the FX-disrupted locus (Figure 6, lanes
1, 6 and 7), whereas DNA isolated from incorrectly targeted Neo-selected ES
clones failed to show a PCR product of any length (Figure 6, lanes 2, 3, 4, 5, 8
and 9).  Among the 192 G418-resistant ES clones analyzed by PCR, 8
individual clones demonstrated successful targeting at the 3' homologous
region.  This PCR reaction using the primer pair indicated in Figure 5C and a
second PCR reaction using a primer pair to amplify the 350-bp exon 8 fragment
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were carried out to genotype offspring resulting from heterozygous FX(+/-)
intercross.  Figure 7 shows the PCR results from the three expected genotypes.
While the 350-bp PCR fragment from exon 8 is shown in the wild-type and
heterozygous samples (Figure 7, lanes 2, 4, 6, and 8), it is absent in the FX
knock-out samples (Figure 7, lanes 10 and 12).  Likewise, the 2.2-kb PCR
product amplified from the 3’ end of the FX knock-out locus is present in the
heterozygous and FX knock-out samples (Figure 7, lanes 5, 7, 9 and 11), and
absent in the wild-type samples (Figure 7, lanes 1 and 3).
Figure 6. PCR analysis of ES cell DNA. ES cell clones correctly targeted at the 3’
recombination site were identified by presence of a 2.2-kb PCR product (lanes 1, 6 and
7).  Incorrectly targeted ES cell clones did not yield any PCR product (lanes 2, 3, 4, 5,
8 and 9) with the primer pair indicated in Figure 5C.
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Figure 7. PCR analysis of mouse genomic DNA. Shown are PCR amplification
products of the three genotypes from heterozygous FX(+/-) intercross. A 350-bp PCR
fragment from exon 8 is present in the wild-type and heterozygous samples (lanes 2, 4,
6 and 8) and absent in the knock-out samples (lanes 10 and 12).  Conversely, a 2.2-kb
PCR product is present in the heterozygous and knock-out samples (lanes 5, 7, 9 and
11) and absent in the wild-type samples (lanes 1 and 3).
2.3.4  Southern blot results
To ensure correct targeting at the 5’ recombination site, EcoRV digested DNA
(from 8 PCR positive out of 192 ES clones analyzed) was hybridized with a
2.8-kb FX probe, corresponding to the 5’ targeting arm (Figures 5B and C).
EcoRV digested genomic DNA (from blood cells of mice) was also hybridized
the 2.8-kb FX probe.  Regardless of its origin (ES cells or blood cells), wild-type
DNA uniformly showed a 4.7-kb fragment (Figure 8, control lane); heterozygous
DNA yielded a 4.7-kb fragment and an additional 7.6-kb fragment (Figure 8,
lanes 1-8 and Figure 9, lane 1); homozygous FX knock-out DNA showed
exclusively the 7.6-kb fragment (Figure 9, lanes 2 and 3).  These results are
consistent with the design of the FX socket vector; the FX knock-out locus
(when digested with EcoRV and hybridized with the 2.8-kb probe) yielded a
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fragment 2.9-kb longer than that produced by the wild-type locus in the same
Southern blot analysis.
Figure 8. Southern blot analysis of ES cell DNA.  Eight correctly targeted ES clones
identified by PCR analysis were also confirmed by Southern hybridization using a 2.8-
kb FX probe (Figures 5B and C).  As predicted, EcoRV digested FX knock-out locus
yielded a fragment 2.9-kb longer than that produced by the EcoRV digested FX wild-
type locus.  DNA samples from the eight correctly targeted ES clones contain a 4.7-kb
wild-type fragment and a 7.6-kb knock-out fragment (lanes 1-8). The control lane
containing DNA sample from a wild-type ES clone shows only the 4.7-kb wild-type
band.
Figure 9. Southern blot analysis of genomic DNA. Genomic DNA isolated from
blood cells of mice was digested with EcoRV and hybridized with a 2.8-kb FX probe
(Figures 5B and C).  Shown here is a Southern blot analysis of DNA from
heterozygous FX(+/-) and FX(-/-) mice.  As expected, DNA from heterozygous mice
yielded a 4.7-kb wild-type fragment and an additional 7.6-kb knock-out fragment (lane
1), where as DNA from FX knock-out mice showed only the 7.6-kb band (lanes 2 and
3).
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2.3.5  Targeting frequency
Of the 192 G418-resistant ES clones isolated and analyzed by PCR, 8 were
correctly targeted, showing a 2.2-kb PCR amplification product from the 3’ end
of the FX knock-out locus (Figure 6).  Subsequently, Southern blot analysis of
all 8 PCR-positive ES clones confirmed correct targeting at the 5’ recombination
site (Figure 8).  Therefore, the overall targeting frequency achieved by the FX
socket vector in E14TG2a cells was 4% (8/192).
2.3.6  Production of FX knock-out mice
Heterozygous FX(+/-) ES clones were expanded, and one expanded clone was
micro-injected into C57/BL6 blastocysts for implantation into the uterine horns
of pseudo-pregnant mice.  Two weeks after the procedure, fifteen animals were
born and seven showed chimerism by their coat color ranging from 75% to
100%.   All chimeric males were mated with wild-type C57/BL6 females; 2 were
fertile and gave rise to F1 offspring.  PCR and Southern blot analyses of DNA
obtained from F1 progeny revealed germline transmission of the FX knock-out
allele from the chimeric fathers (results not shown).  Furthermore, 50% of the
F1 offspring were heterozygous for the FX-disrupted allele.  Taken together,
these results showed not only germline transmission, but also autosomal
inheritance of the affected allele.  Following their identification, heterozygous
FX(+/-) mice were intercrossed to obtain homozygous FX(-/-) offspring for
characterization of the phenotype induced by complete FX deficiency.
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2.3.7  Phenotypic characterization of FX knock-out neonates
While no phenotypic difference was observed between FX(+/+) and FX(+/-)
neonates, 26 homozygous FX(-/-) neonates examined were readily
distinguished from their normal littermates by rapid development of an overall
pale appearance shortly after birth.  A closer inspection of FX-null pups
revealed an obvious accumulation of blood in the abdominal cavity (Figure 10).
The majority of homozygous FX(-/-) neonates (23 out of 26) developed severe
intra-abdominal hemorrhage within hours of birth and died within 24 hours after
delivery (Figure 11).  In the absence of a more commonly observed intra-
abdominal hemorrhage, 3 FX knock-out pups from 3 different litters instead
manifested subcutaneous bleeding mostly over the head, back, neck area, and
the limbs (Figure 12).  Those few were able to survive for 2-4 days (Figure 11).
Interestingly, FX-null pups were indistinguishable from their normal littermates
at birth.  Only after development of a hemorrhagic phenotype within a few hours
of birth, were they readily identified by their pale appearance.  By gross
examination, FX knock-out mice appeared normal, showing no obvious signs of
anatomical defects that would prevent post-natal survival.
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Figure 10. Phenotypic comparison of FX(+/+) and FX(-/-) neonates. The majority of
FX knock-out pups developed severe intra-abdominal hemorrhage (arrows) and
succumbed within 24 hours of birth.
Figure 11. Kaplan-Meier survival curve of homozygous FX knock-out mice.  23/26
mice died within 24 hrs of birth and the remaining 3 suffering from subcutaneous
bleeding also succumbed within the next three days.
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Figure 12. Subcutaneous bleeding in a FX(-/-) mouse. As shown here, few FX
knock-out mice showed subcutaneous bleeding mostly over the head, back, neck area,
and the limbs.
2.3.8  Genotype analysis of the offspring from heterozygous FX(+/-)
intercross
DNA analysis of the full-term offspring (n=213) resulting from mating of
heterozygous FX (+/-) mice identified 76 (36%) FX (+/+), 111 (52%) FX (+/-),
and 26 (12%) FX(-/-) (Table 2).  Representation by the FX(-/-) mice (12%) was
significantly smaller (p<0.001) than the expected percentage (25%) derived
from the Mendelian law of an autosomal inheritance. These results suggested
that some FX knock-out mice might have suffered embryonic lethality.
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Table 2. Genotype distribution among offspring from heterozygous FX(+/-)
intercross.
2.3.9  Evaluation of embryonic lethality and phenotype of FX knock-out
mice
To verify intrauterine lethality, FX-null embryos from mating of heterozygous
FX(+/-) mice were examined at various time points during development (Table
3).  It was noted that as early as E10.5, viable FX(-/-) embryos accounted for
only 14% of the total progeny (n=84) (Table 3).  Data were similar at E11.5
(Table 3) with FX-null embryos also representing 14% (p<0.05) of the total
progeny (n=104).  In the later stages of development, there was little change in
the survival of FX(-/-) embryos, leading to FX knock-out mice representing 12%
of the offspring (n=213) at birth or approximately 50% of the expected number
of FX-null mice (Tables 2 and 3).   Interestingly, at various stages of
development, viable FX knock-out embryos were indistinguishable by gross
examination from their wild-type and heterozygous littermates.  Furthermore, no
evidence of obvious bleeding was found with either viable or reabsorbed FX
knock-out embryos at various developmental stages.   For those FX knock-out
mice that survived to term, 23 out of 26 died within 24 hours from intra-
abdominal hemorrhage, and the remaining 3 suffered from fatal subcutaneous
bleeding within four days of birth (Figure 11).
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Table 3.  Genotype distribution among offspring of heterozygous FX(+/-) parents
2.3.10  Detection of a partial transcript in FX knock-out mice
Since exon 8 was the only coding sequence eliminated in the design of the FX
socket-targeting vector (Figure 5A), one might expect the presence of a partial
transcript in FX-null mice.  This expectation was confirmed by the results of RT-
PCR (Figure 13): two pairs of upstream primers (all 5’ to exon 8 sequence)
yielded a 705-bp fragment (from exons 1 to 6) and a 390-bp fragment (from
exons 5 to 7) for both wild-type and FX knock-out samples (Figure 13, lanes 1-
4).  However, when amplified with exon 8-specific primers, only the wild-type
sample and not the knock-out sample gave rise to the expected 350-bp PCR
product (Figure 13, lanes 5 and 6).  Regardless of the genotype, the control
primers yielded a 202-bp β-actin PCR product in all samples (Figure 13, lanes 7
and 8).  Thus, consistent with the overall design of the FX socket vector, RT-
PCR results revealed a partial transcript in FX knock-out mice.
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Figure 13. RT-PCR analysis of FX transcript from FX(+/+) and FX(-/-) neonates.
The odd-numbered lanes contain RT-PCR products from a FX(+/+) neonate and the
even-numbered lanes contain RT-PCR products from a FX(-/-) pup.  In lanes 1-4, RT-
PCR products were amplified, using two pairs of primers specific for sequences 5’ to
the deleted exon 8 sequence. In lanes 5 and 6, RT-PCR product was amplified, using
FX exon 8 specific primers.  Note the absence of an amplification product in lane 6
containing sample from the FX knock-out pup.  Lanes 7 and 8 show RT-PCR products
for the beta-actin transcript.
Northern blot analysis on total RNA extracted from liver revealed an
expected 1.4-kb FX transcript in wild-type neonates, the same signal of less
intensity in heterozygous mice, and absence of this signal in the homozygous
FX knock-out mice (Figure 14).  Instead, a faintly discernible 2-kb transcript was
noted in the total RNA of the homozygous FX(-/-) neonates (Figure 14).  The
low signal of the 2-kb band is likely due to the targeted replacement and thus
absence of the putative FX polyadenylation signal sequence (ATTAAA) in the
knock-out allele.  The authenticity of the weak 2-kb signal from the targeted
allele is supported by its presence in RNA from heterozygous mice and its
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absence in RNA from wild-type samples. The amount and quality of the RNA
samples analyzed on Northern blot were similar based on the signal intensities
of a 1.9-kb β-actin control (results not shown).
Figure 14. Northern blot analysis of total RNA from FX(+/+) , FX(+/-) and FX(-/-)
livers.  While an expected 1.4-kb FX transcript was detected in wild-type and
heterozygous samples, it was clearly absent in the knock-out sample.  Instead, a faintly
discernible 2-kb signal was noted in the knock-out sample; Authenticity of the signal is
supported by its presence in an heterozygous sample and its absence in a wild-type
sample.
2.3.11 Absence of FX antigen in FX(-/-) neonates
To determine whether a protein was synthesized from the partial FX transcript,
Western blot analysis was performed on plasma from wild-type, heterozygous,
and homozygous FX knock-out mice.  All primary antibodies used in Western
blot analysis were previously tested and shown to cross-react with a 54-kDa
signal corresponding to the mouse FX protein (results not shown).  Despite
detection of low levels of a partial transcript in FX knock-out pups, the 54-kDa
mouse FX protein present in both wild-type and heterozygous mice is clearly
absent in the knock-out newborn mice (Figure 15).  Consistent with the
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genotypes of mice, the noted 54-kDa band intensity is respectively reduced in
the heterozygotes compared to wild-type for both adult and newborn mice
(Figure 15).  This result suggests that, if a protein is synthesized at all from the
partial FX transcript, it is either unstable or not secreted into the circulation.  To
address the question of whether a protein is synthesized but not secreted, cell
lysates were prepared from liver tissue of FX(+/+), FX(+/-), and FX(-/-) neonates
and analyzed on a Western blot; this analysis again failed to disclose a FX
signal in the FX(-/-) samples (Figure 16).  Low levels of a partial transcript
(Figures 13 and 14) and the absence of a detectable protein in FX-null mice
(Figures 15 and 16) confer generation of a mouse model with complete lack of
FX.
Figure 15. Western blot analysis of plasma from FX(+/+), FX(+/-) and FX(-/-) mice.
Note the absence of a 54-kDa mouse FX protein in plasma of FX (-/-) newborn mice.
This signal was readily detected in plasma of wild-type and heterozygous newborn and
adult mice (FX knock-out mice did not survive into adulthood).
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Figure 16. Western blot analysis of cell lysates from FX(+/+), FX(+/-) and FX(-/-)
livers.  A 54-kDa mouse FX protein is readily observed in the liver cell lysates of wild-
type and heterozygous mice (lanes 2 and 3); this signal is absent in the sample from a
FX knock-out mouse (lane 4).  A 59-kDa human FX protein (Haematologic
Technologies Inc.) is shown as positive control for this analysis (lane 1).
2.3.12  Coagulation activities of plasma from FX(-/-) newborn mice
In an aPTT-based assay, plasma from FX(+/+) and FX(+/-) neonates did not
yield averaged clotting times statistically different from each other (Table 4) or
from that of pooled normal mouse plasma (data not shown), while plasma from
FX(-/-) pups revealed significantly reduced coagulation activities as
demonstrated by a two-fold increase in averaged clotting time when compared
to that of wild-type plasma (Table 4).   Likewise, a PT-based assay revealed
lack of a remarkable difference in averaged clotting times between wild-type
and heterozygous plasma, but demonstrated complete failure of homozygous
FX knock-out plasma to form a fibrin clot; no clot formation was detected within
a reasonable length of time (Table 4).
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Table 4. Coagulation times in seconds of FX(+/+), FX(+/-), and FX(-/-) newborn
plasma. (aPTT=1:40 dilution; PT=1:80 dilution)
2.3.13  Immuno-staining of E13.5 embryo sections for PECAM-1 and
ICAM-2
PECAM-1 is expressed on endothelial cells and mediates cell-to-cell
interactions in angiogenesis.59,60   ICAM-2 is a cell surface glycoprotein that is
expressed on endothelial cells, T cells, and B cells.61,62 Paraffin-embedded
sections from E13.5 wild-type and FX knock-out embryos were immuno-stained
for the two endothelial cell-associated markers, PECAM-1 and ICAM-2 (Figure
17).  For both markers, no obvious difference in the staining pattern was
observed between the FX knock-out and wild-type embryos at this stage of
development.
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Figure 17.  Immuno-staining of E13.5 embryo sections for PECAM-1 and ICAM-2.
The upper panels show PECAM-1 staining of paraffin-embedded sections from a wild-
type (A) and a FX knock-out embryo (B).  The lower panels show ICAM-2 staining of
paraffin-embedded sections from a wild-type (C) and a FX knock-out embryo (D).  For
both markers, no remarkable difference in the staining pattern was noted between
E13.5 wild-type and FX knock-out embryos.
2.4  Discussion
Despite a more selective deletion (deletion of exon 8 only), FX knock-out mice
generated in this study showed a phenotype similar to that of a previously
reported FX knock-out mouse model, in which exons 2 to 8 had been
eliminated.63  Similar to the other model, our model of complete FX deficiency
resulted in embryonic lethality in approximately 50% of FX-null mice and fatal
perinatal bleeding in the remaining half that survived to term, although the
proportion of FX-null mice at birth, and the length of postnatal survival were not
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identical in the two models.  These minor variations might be attributed to
different strains of ES cells and mice used to generate the two mouse models.
Whereas the other model was generated on 50/50 R1 129/Swiss mixed genetic
background,63 our model was engineered on E14TG2a (derived from 129/Ola
Hsd), C57/BL6, and SvJ 129 mixed genetic background.  Although both models
of complete FX deficiency result in similar phenotypes, use of the plug-and-
socket targeting strategy here readily facilitates rescue of FX-null mice.
The data presented here show that approximately half of the expected
numbers of FX-null mice were accounted for at birth (Table 2), and 100% of
these FX-null mice died within four days of birth; the majority of these mice
(~90%) succumbed within 24 hours of birth from intra-abdominal hemorrhage
(Figure 11).  Among the 26 FX-null mice examined, 3 manifested subcutaneous
bleeding and survived up to 4 days following birth.  With the exception of the
bleeding diathesis described above, FX-null mice appeared otherwise normal
by gross examination.  No phenotypic differences were noted between wild-type
and heterozygous FX mice.
Approximately 50% of FX knock-out mice suffered embryonic death.
Timed mating of heterozygous FX(+/-) mice and analysis of their offspring
disclosed that as early as E11.5 (Table 3), viable FX-null embryos were
significantly under-represented, accounting for 14% rather than the expected
25% of the total progeny (p<0.05).   Presumably, death of FX knock-out
embryos had occurred earlier at E10.5 or before.  Thereafter, there was little
change in the survival of FX(-/-) embryos, with FX knock-out mice representing
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12% of the offspring at birth.  These findings are consistent with data presented
in the other study, in which it was shown that 17% and 15% of the progeny
were respectively viable FX-null embryos at E12.5 and FX knock-out mice at
birth.63 Thus, this investigation together with the other report helps to define a
critical period in development (~E10.5 to E12.5), in which FX plays an important
yet elusive role in embryonic survival.
While perinatal lethality of FX knock-out mice is thought to be due to
defective hemostasis (i.e. failure in thrombin generation), the underlying cause
of embryonic lethality occurring in the absence of obvious evidence of bleeding
remains to be investigated.  Although several hypotheses have been offered to
explain the cause(s) of embryonic lethality observed for deficiencies in a
number of hemostatic components, no definitive data have been provided.  The
complex nature of the observed phenomenon can be better understood with
consideration of the following example in FX deficiency.  On the one hand, one
can conjecture that the failure of FX knock-out mice to generate thrombin is
embryonically lethal since it impairs not only platelet activation, but also soluble
fibrin clot formation.  If true, this would reasonably explain why mice lacking
either FV (recall that FXa and FVa work in concert to generate thrombin) or
prothrombin (FII) (prothrombin is the catalytically inactive zymogen of thrombin)
showed a parallel pattern of embryonic loss, whereas mice deficient in
fibrinogen completed embryonic development and were born at the expected
Mendelian frequency, presumably because these mice still had catalytically
active thrombin that is able to achieve minimal platelet activation.6,10-12   On the
43
other hand, consideration of additional evidence and observation brings into
question this explanation for embryonic death in FX knock-out mice.   Upon
examination, neither viable nor reabsorbed FX knock-out embryos showed
evidence of bleeding (this observation was based on inspection of embryos at
various stages of development).  Specifically, absence of obvious bleeding in
FX knock-out embryos harvested from a critically defined period of development
(~E10.5 to E12.5) makes hemorrhage unlikely as the deciding cause of
embryonic lethality. The timing of intrauterine lethality (E10.5 to E11.5) in FX-
knockout mice also challenges defective hemostasis as the underlying cause
since the liver organ is just forming at E10.5, and for this reason, there is likely
little generation of catalytically active thrombin in E10-11 day embryos.
Furthermore, FX protein synthesized between E10.5 and E11.5 is unlikely to
have activity in thrombin generation due to the absence of a functional γ-
glutamylcarboxylase enzyme system.  Essential for the activity of all vitamin-K
dependent coagulation factors including FX, this enzyme is not expected to be
fully functional until later stage of mouse development as it is not expressed
until E16.5 in rat liver (rat gestation = 22 days; mouse gestation = 19 days).64
Finally, absence of intrauterine lethality in mice lacking FVII, a crucial factor in
the initiation of blood coagulation, would also challenge defective hemostasis as
the underlying cause of embryonic loss.1   As a matter of fact, suggestions of an
additional non-hemostatic role during development have already been made for
several hemostatic components including FV, FII, TF, TM, and TFPI.10-17
Taken together, these observations suggest that embryonic lethality of FX-null
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mice might be attributed, not to its impaired coagulation, but rather to a
biological function of FX that is yet to be defined.
Still the observation of incomplete or partial block to embryonic survival
cannot be readily reconciled by suggestion of a non-hemostatic or
developmental role for some hemostasis-related factors including FX.
Seemingly, the embryonic requirement for FX is not absolute, since
approximately half of FX knock-out mice developed to term (although they all
succumbed to fatal hemorrhage within a few days of birth).  Conversely, it may
be that the embryonic need for FX is indispensable, and developmental
success of some FX knock-out embryos may be attributed to variable maternal
transfer of FX, sufficient to support embryonic survival of some but not all FX-
null embryos.  Whether the partial embryonic lethality of FX-deficient mice is
due to lack of an absolute requirement for FX or due to variable maternal
transfer of indispensable FX remains to be deciphered.
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3. Generation and characterization of FX knock-in mice
3.1  Introduction
As shown in the previous chapter, our mouse model of complete FX deficiency
resulted in partial embryonic lethality and fatal perinatal bleeding.  Namely,
approximately 50% of the expected numbers of FX-null mice died during
development with the remaining half progressing to term to succumb to fatal
bleeding within a few days of birth.  This finding in a mouse model of complete
FX deficiency is consistent with the absence of humans homozygous for
deletions in the FX gene.  Furthermore, these results affirm the importance of
FX in supporting both embryonic and postnatal survival.
Early mortality of FX knock-out mice precludes their use as a viable model
of severe FX deficiency.  Rescue of these mice would afford a myriad of
analyses that are otherwise unfeasible.  Generation of a viable mouse model of
severe FX deficiency would provide unique opportunities 1) to decipher specific
characteristics of a FX variant that are able to rescue either just the embryonic
lethality or both embryonic and peinatal lethality, since the underlying cause of
embryonic lethality may not be due to failure in thrombin generation, believed to
be the cause of perinatal lethality; 2) to characterize specific phenotypes
(morphological and pathological conditions) associated with expression of a
specific FX variant; and 3) to examine the contribution of maternal FX during
development.  First, female mice rescued with minimal levels of FX activity can
be utilized in a breeding experiment to generate offspring with even lower levels
of FX activity.  Second, these mice with further reduced FX activity can then be
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assessed for their viability and furthermore be used to investigate any evidence
for contribution of maternal FX to embryonic survival.
That being said, how can FX knock-out mice suffering from embryonic and
perinatal lethality be rescued for further studies?  Is full catalytic activity of FX
required for rescue?  Will FX-deficient mice overcome both embryonic and
postnatal challenges with restoration of minimal levels of catalytically active FX?
Conversely, can a catalytically inactive FX molecule created by elimination of a
functional active site support embryonic development, even though full-term
mice with such a severe molecular defect are expected to succumb to fatal
hemorrhage due to their inability to generate thrombin?   Nonetheless, the goal
here is not to define the minimal characteristics of FX protein required for
rescue (which is not feasible with study of a single FX variant), but to rescue FX
knock-out mice from lethality and reveal those characteristics of a variant that
are able to achieve rescue.
Recall exon 8 encoding the catalytic domain of the protein was the only
coding region of the FX gene that was deleted in the design of the socket
construct used to generate the FX knock-out mice.  Hence, to re-establish any
minimal levels of FX catalytic activity or FX antigen (FX knock-out mice
generated here do not have any FX activity or antigen), exon 8 with a desired
mutation must be restored in the previously knock-out FX locus, using an
appropriately designed plug construct.  As described earlier, this rescue of the
FX locus is made convenient with the use of a plug-and-socket targeting
strategy.
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While no homozygous deletions of the FX gene in humans have ever been
reported (this observation is reaffirmed by the lethal phenotype of FX knock-out
mice), mutations in exon 8 alone (mostly missense mutations) account for more
than 50% of all mutations described for the FX gene.  This finding is not
statistically surprising, considering that exon 8 is the largest exon in the FX
gene.  With respect to the rescue experiment presented here, only mutations
found in exon 8 of the FX gene are relevant for consideration.  For the purpose
of illustration, Table 5 provides a small list of naturally occurring human FX
variants with specific mutations in exon 8, their corresponding levels of FX
activity and antigen, and their respective clinical phenotypes.  Factor X
mutations can be readily found on http://www.med.unc.edu/isth/mutations-
databases/Factor_X.htm.
Table 5. A list of some naturally occurring human FX variants with mutations in
exon 8.
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It is important to note that mouse and human FX proteins are over 70%
similar in their amino acid sequences (with the highest conservation observed in
the amino acid sequence for the catalytic domain).26   Furthermore, exon 8
mutations shown in Table 5 occur at particular residues that are conserved for
blood coagulation FX among several species, suggesting that an analogous
mutation, when introduced into the mouse FX gene, will encode a FX variant
that is likely to exhibit structural and functional characteristics similar to those
described previously for the respective human FX mutation.  However, with no
knowledge of whether minimal FX catalytic activity or FX antigen (e.g. FX
molecule that lacks any catalytic activity) is required to achieve minimally the
embryonic rescue of FX-knockout mice, selection of a FX variant with normal
antigen levels and reasonable levels of FX catalytic activity seems appropriate
to attempt rescue of FX knock-out mice.   For these reasons, a specific human
FX variant (FX Friuli) with a mutation in exon 8 was selected to attempt rescue
of FX-knockout mice.  As indicated in Table 5, FX Friuli resulting from
substitution of Serine (TCC) for Proline (CCC) at amino acid 343 shows 4-9%
FX activity and normal antigen levels in humans.65
First identified in a population of patients in the Friuli region of Italy, FX Friuli
is associated with a homozygous point mutation (C to T transition at nucleotide
position 19,297) that results in the substitution of serine for proline at amino
acid position 343.65   This change occurs at a highly conserved proline residue
that is part of a 14 residue motif (L∗∗∗∗∗P∗∗∗∗∗∗C) found in at least 16 other
members of the serine protease superfamily.65   Patients who are homozygous
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for this point mutation have demonstrated moderate bleeding tendency, and
both prolonged prothrombin and partial thromboplastin times that correspond to
FX activity levels of 4% to 9% of nomal.  However, these patients show normal
levels of FX antigen in their plasma.  As a result of C to T transition at
nucleotide number 19,297, a BanI restriction site present in exon 8 of the wild-
type FX gene is abolished in FX Friuli.65   Accordingly, this base change is
utilized in the design of a screening method to discriminate FX Friuli mice from
wild-type mice.
The objectives of the work described in this chapter are 1) to rescue FX
knock-out mice from lethality by generating a viable mouse model of FX
deficiency, 2) to determine specific characteristics of a FX variant that are
capable of effecting a rescue, 3) to delineate morphological and/or pathological
conditions associated with expression of a specific FX variant, 4) to uncover
additional evidence for a non-hemostatic role of FX in development, and 5) to
assess contribution of maternal FX to embryonic survival.
3.2  Materials and methods
3.2.1  Construction of the FX plug-targeting vector
Plasmid vector pCI-mFX-3’ containing the 7-kb 3’ end of mouse FX genomic
sequence (Figure 18A) was digested with SphI to release a 2.4-kb fragment.
The resulting insert containing FX exon 8 sequence was then ligated with SphI
digested pGEM-3Z plasmid vector (Progema) to produce a correctly oriented
insert-to-vector template (pGEM-3Z-exon 8) (Figure 18B).  In an in vitro site-
directed mutagenesis reaction containing this plasmid template (QuikChange
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Multi-Site Directed Mutagenesis kit, Stratagene), a pair of mutagenic primers
(forward: 5’-CCTGAAGATGCTGGAGGTATCCTACGTGGATCGCAACACC-3’
and reverse: 5’-GGTGTTGCGATCCACGTAGGATACCTCCAGCATCTTCAGG-
3’) designed to make the desired substitution of TCC for CCC in exon 8 was
used to generate the Friuli mutation.  To obtain the rest of FX genomic
sequence from pCI-mFX-3’ that is upstream from the first SphI site, pCI-mFX-3’
was digested sequentially with MfeI and SalI to release a ~4.1-kb FX fragment.
This fragment was then subcloned into the MfeI/SalI digested pGEM-3Z-exon 8
plasmid, yielding a 8.1-kb plasmid (pGEM-3Z-mFX 3’) (Figure 18C).
Subsequently, to generate the final FX-plug construct (pBY9-mFX plug, Figure
18D) for the knock-in experiment, a 5.3-kb FX sequence (including exons 6, 7
and 8 mutated, and intron sequences) was removed from SalI//HindIII  digested
pGEM-3Z-mFX 3’ plasmid, and cloned into the XhoI/HindIII digested pBy9 plug
vector (provided by Dr. Randy Thresher, UNC Chapel Hill).  Spanning about
10.2-kb in length, the final FX plug-targeting vector contains the identical 2.8-kb
5’ targeting arm as the FX socket-targeting construct and a 1.4-kb 3’ targeting
arm (Figure 18D).  Necessary for the reconstitution of HPRT sequence, the 3’
arm provides a region of HPRT sequence that overlaps with that in the pPD20
plasmid (used to engineer the FX socket construct). The specific substitution to
confer the Friuli mutation was confirmed with dideoxynucleotide sequencing
before electroporation of the FX plug construct.
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Figure 18. Construction of the FX plug-targeting vector. (A) pCI-mFX-3’ contains
the 7-kb 3’ FX genomic sequence.  (B) pGEM-3Z-exon 8 contains the Friuli mutation in
exon 8 after an in vitro site-directed mutagenesis.  (C) pGEM-3Z-mFX 3’ contains the
3’ FX sequence (with Friuli mutation) that is absent in the FX knock-out locus.  (D)
pBY9-mFX plug containing the Friuli mutation in exon 8 is the final FX plug-targeting
vector used in the rescue experiment.
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3.2.2  Electroporation and selection of HAT-resistant ES cell clones
ES cells were grown on irradiated murine embryonic fibroblasts (MEFs) in
HEPES buffered (10 mM) Dulbecco's modified Eagle's medium (DMEM),
supplemented with 15% fetal calf serum (FCS), 0.1 mM non-essential amino
acids, 2 mM L-glutamine, 0.1 mM β-mercaptoethanol, 1000 U/ml leukemia
inhibitory factor (LIF), and 50 µg/ml of Gentamycin. HPRT-negative murine ES
cells heterozygous for deletion of exon 8 (from the original targeting event) were
electroporated with 100 µg/ml of SapI linearized FX plug construct, using the
same electroporation conditions as previously described in Chapter 2.  Twenty-
four hours after electroporation, transfected ES cells seeded on HPRT-positive
feeder layers were grown in the culture medium supplemented with HAT (120
µM hypoxanthine/0.4 µM aminopterine/20 µM thymidine).  HAT selection lasted
for 7-10 days before DNA isolated from the individual HAT-resistant ES clones
(i.e. clones with reconstituted HPRT sequence) was analyzed by PCR and
Southern hybridization.
3.2.3  Isolation of ES cell DNA and mouse genomic DNA
To analyze HAT-resistant ES cell clones for homologous recombination, DNA
was isolated using the Easy DNA Kit (Invitrogen, Carlsbad, CA).  To genotype
for mice carrying the Friuli mutation, genomic DNA was extracted from blood
samples collected from the retro-orbital plexus into heparin-containing micro-
capillaries, and purified using the QIAamp DNA Blood Mini Kit (Qiagen,
Valencia, CA).
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3.2.4  PCR analyses on ES cell DNA and mouse genomic DNA
DNA from HAT-resistant ES clones was first subject to PCR analysis, using two
specific primers (little arrows in Figure 19C) (forward primer: 5’-
AGGCACCCCCAGGCTTTACAC-3’ annealing to a HPRT sequence present
only in the pBY9 vector and reverse primer: 5’-
TCGAGGCTGCAGTGAGCAGTG-3’ annealing to a downstream HPRT
sequence unique in the pPD20 vector).66   Presence of a 1.6-kb amplification
product in DNA samples identified those HAT-resistant ES clones that not only
contain the reconstituted HPRT sequence, but also demonstrate homologous
recombination at the 3’ end.  DNA samples positively identified by the last PCR
reaction were further analyzed for the absence of a BanI site in a 350-bp exon 8
PCR product amplified from the mutated FX allele.  To differentiate FX(F/F),
FX(+/F), and FX(+/+) mice by PCR analysis, the same 350-bp exon 8 PCR
product (amplified with primers described above) was digested with BanI and
analyzed on 2% TAE gel (note: presence of the Friuli mutation results in
elimination of the BanI site within the 350-bp exon 8 PCR product).
3.2.5  Southern blot analysis on ES cell DNA and mouse genomic DNA
DNA from HAT-resistant ES clones and mice (positively identified by prior PCR
analysis) was further examined by restriction enzyme digest with EcoRV and
Southern hybridization.  The 2.8-kb FX sequence that served as the 5’ targeting
arm in both FX socket and FX plug constructs was used as a probe labeled with
32P-dCTP in a random priming reaction.
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3.2.6 DNA sequencing to confirm substitution of TCC for CCC in FX
exon 8
The 350-bp exon 8 PCR product amplified from DNA samples extracted from
HAT-resistant ES clones (first identified by a separate PCR reaction and
Southern hybridization) and the same 350-bp PCR product amplified from
genomic DNA of mice (either offspring of chimeric mice or offspring of
heterozygous FX(+/F) mice) were subjected to dideoxynucleotide sequencing to
confirm the substitution of TCC for CCC (corresponding to amino acid 340 in
mouse FX) in exon 8 of FX gene.26
3.2.7  Generation of homozygous FX-Friuli [FX(F/F)] mice
Production of all chimeric mice was performed by the Transgenic & Chimeric
Mouse Facility of the University of Pennsylvania.  Individual FX(+/F) murine ES
cell clones were expanded; one was micro-injected into C57/BL6 blastocysts for
implantation into the uterine horns of pseudo-pregnant mice.  Chimeric males
were mated with wild-type C57/BL6 females to produce heterozygous FX(+/F)
offspring, which were intercrossed to obtain homozygous  FX(F/F) mice for
detailed characterization.
3.2.8  Western blot analysis of plasma
Collected from four weeks-old FX(+/+) and homozygous FX(F/F) mice, blood
samples were processed as described above to obtain plasma for Western blot
analysis.  Plasma samples (1:5 and 1:20 dilutions) were separated by
electrophoresis in 10% SDS/12% Tris-HCL polyacrylamide gels (Bio-Rad,
Hercules, CA) under denaturing conditions, and transferred onto a Hybond ECL
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nitrocellulose membrane (Amersham Pharmacia Biotech.).  After blocking, FX
antigen was incubated with and immunodetected by a horseradish-peroxidase
conjugated rabbit anti-human FX polyclonal antibody (1:300 dilution)
(Cedarlane, Ontario, Canada).  Signals from the FX/antibody-HRP complex
were visualized by applying the chemiluminesce reagents as instructed from the
manufacturer (Amersham Pharmacia Biotech.).
3.2.9  Generation of FX(-/F) mice
To generate and characterize mice with even lower levels of FX activity,
homozygous FX(F/F) female mice were mated with heterozygous FX(+/-) male
mice.  Note female rather than male FX(F/F) mice were selected in this
breeding scheme to evaluate their reproductive fitness. Two distinct PCR
reactions were used to ensure correct genotypic analysis of FX(-/F) and FX(+/F)
offspring from this cross.   From the first PCR reaction, a 350-bp exon 8 PCR
product was subject to BanI restriction digest to differentiate mutated exon 8
(carrying the Friuli variant) from wild-type exon 8.  Furthermore, to confirm
presence of a Neo sequence in FX(-/F) mice and its absence in FX(+/F) mice,
two specific primers (forward primer: 5’-GCCGCGCTGCCTCGTCCTG-3’
annealing to a sequence in the Neo gene and reverse primer: 5’-
CCAAACCCCGCCATTCCGTCCTC-3’ annealing to a sequence in the 3’HPRT
minigene) found only in the socket vector used to generate the knock-out FX
allele were applied in a second PCR reaction.  FX(-/F) offspring resulting from
this mating were further characterized and compared with FX(+/+) mice.
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3.2.10  Activated partial thromboplastin time (aPTT) and prothrombin time
(PT) FX assays
Blood samples collected from tails of 4 to 6 weeks-old adult mice [FX(+/+),
FX(+/F), FX(F/F), and FX(-/F)] were combined with one-tenth volume of 3.8%
sodium citrate and centrifuged at 9000 rpm for 10 minutes in 4°C to obtain
plasma for measurement of FX coagulation activities by aPTT and PT assays.
To measure FX clotting activities by aPTT, 50 µl of plasma sample diluted (1:2
to 1:80) with imidazole buffer (Hedwin, Baltimore, MD) was mixed with 50 µl of
human FX-deficient plasma (Biomerieux, Durham, NC) and 50 µl of aPTT
reagent (Biomerieux); the mixture was incubated at 37° C for 3 minutes before
the addition of 50 µl of 25 mM CaCl2 to initiate clot formation.  To measure FX
clotting activities by PT, 50 µl of plasma sample diluted (1:2 to 1:80) with
imidazole buffer was combined with 50 µl of human FX-deficient plasma, and
incubated at 37° C for 3 minutes before the addition of 100 µl pre-warmed
thromboplastin reagent (Biomerieux).  Time elapsed in seconds before each
clot formation was determined with a fibrometer (Fibrosystem; BBL,
Cockeysville, MD).   Based on the values of pooled normal mouse plasma (1:10
to 1:200 dilutions), standard curves for the aPTT and PT FX assays were
respectively generated to convert clotting times to percent normal FX activities.
3.2.11  Genotypic analysis of offspring from mating of FX(-/F) mice
Reproductive fitness of FX(-/F) mice, male and female, was evaluated and
compared to that of their respective wild-type mice.  Full-term offspring resulting
from mating of FX(-/F) mice were genotyped according to the two PCR
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screening strategies described earlier.  For each expected genotype [FX(F/F),
FX(-/F), and FX(-/-)], the numbers of offspring observed were compared to the
numbers of offspring expected based on the Mendelian frequency of autosomal
transmission.   Numerical differences were analyzed by the chi square test.
3.2.12  Phenotypic analysis of embryos resulting from FX(-/F) mothers
To investigate the embryonic phenotypes of several FX-deficient genotypes as
littermates, FX(-/F) females were mated with heterozygous FX(+/-) males.
From this mating scheme, four different FX-deficient genotypes [FX(+/-),
FX(+/F), FX(-/F), and FX(-/-)] were possible for phenotypic characterization.
Timed mating was set up between FX(-/F) females and FX(+/-) males; embryos
from the cross were harvested and analyzed at critical time points (E10.5,
E11.5, and E12.5) during development.  Subsequent to microscopic
examination, the genotype of each embryo was confirmed by analysis of its yolk
sac DNA.
3.2.13  Histological analysis of FX-deficient mice
Adult mice of various ages were sacrificed by CO2 inhalation; organs were
harvested, washed in PBS, and fixed in 10% formalin overnight at 4°C.
Tissues were embedded in paraffin, sectioned (5 µm in thickness), and stained
with Prussian blue, or Masson’s trichrome stain, using standard protocols.
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3.3  Results
3.3.1  Homologous recombination between the FX plug-targeting vector
and FX knock-out locus
Following homologous recombination between the FX plug construct (Figure
19B) and FX knock-out locus resulting from the first targeting experiment
(Figure 19A), the Neo gene is replaced by exon 8 carrying the Friuli mutation,
and concomitantly the HPRT minigene is reconstituted (Figure 19C) for HAT-
resistance selection of ES cells.   [Note as the result of this homologous
recombination event, correctly targeted ES cells are G418-sensitive and HAT-
resistant].
Figure 19. Targeted knock-in of FX-Friuli. (A) The 3’ end of FX knock-out locus
shows the deleted exon 8 replaced by Neo and partial HPRT minigene cassette.
Figure 19 (continued)
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The little arrows below the cassette indicate the location of a primer pair used in a PCR
reaction to differentiate FX(-/F) mice from FX(F/F) mice. (B) FX plug construct contains
the Friuli mutation in exon 8 (∗) and supplies the missing 5’ portion of an HPRT
minigene. Its 5’ targeting arm is the same 5’ arm in the FX socket construct and its 3’
targeting arm contains a 1.4-kb overlapping HPRT sequence with the FX socket
construct. (C) Following homologous recombination, Neo gene is replaced by the
mutated exon 8 and the HPRT minigene is reconstituted for HAT medium selection.
The two arrows below the reconstituted HPRT sequence indicate the location of a
primer pair used in a PCR reaction to identify correctly knock-in ES clones. The
darkened bar below exons 6 and 7 represents a probe used in Southern hybridization.
With knock-in of exon 8, the distance (4.7-kb) between two adjacent EcoRV sites at the
3’ end of the FX gene is also restored as indicated by the length of a double-head
arrow.
3.3.2  PCR results
Among the 48 HAT-resistant ES clones analyzed, clones that were correctly
targeted by the FX plug construct revealed not only a 1.6-kb PCR product
amplified from the reconstituted HPRT sequence (Figure 19C), but also a 350-
bp exon 8 PCR product that is not subject to BanI restriction digest, in addition
to the wild-type fragment that is subject to the restriction digest (results not
shown).   Genotypes of mice [FX(+/+), FX(+/F), and FX(F/F)] were revealed
based on the results of BanI digest of the 350-bp exon 8 PCR product (Figure
20): wild-type samples (lanes 1, 6, and 7) yielded two fragments (250-bp and
100-bp), heterozygous FX(+/F) samples (lanes 3, 4, 5, and 8) showed three
fragments (350-bp mutated exon 8, 250-bp, and 100-bp), and the only
homozygous FX(F/F) sample (lane 2) showed a mutated and thus uncut 350-bp
fragment.
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Figure 20. PCR and restriction enzyme digest (BanI). To genotype FX(+/+),
FX(+/F), and FX(F/F) mice, a 350-bp PCR product amplified across the region of exon
8 containing the Friuli mutation was digested with BanI.  Presence of the Friulil
mutation abolishes the BanI site.  After BanI digest, wild-type exon 8 yields two
fragments (lanes 1, 6, and 7), exon 8 heterozygous for the Friuli mutation shows three
fragments (lanes 3, 4, 5, and 8), and exon 8 homozygous for the Friuli mutation fails to
be digested as shown by a single fragment (lane 2).
Two PCR reactions were carried out to distinguish among FX(-/F), FX(F/F), and
FX(+/F) mice.  While BanI digest of the 350-bp exon 8 PCR product could be
used to differentiate FX(F/F) and FX(-/F) mice from FX(+/F) mice, this PCR
reaction itself was insufficient to make a distinction between FX(F/F) and
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FX(-/F) mice since both genotypes gave rise to a single undigested fragment
(Figure 21A).   To differentiate FX(-/F) mice from FX(F/F) mice, a second PCR
reaction using a primer pair shown in Figure 19A was carried; this reaction
resulted in a 600-bp Neo/ΔHPRT PCR product that is present in FX(-/F) mice
and absent in FX(F/F) mice (Figure 21B).
Figure 21. PCR analysis to differentiate FX(+/F), FX(F/F), and FX(-/F) mice.
Two simultaneous PCR reactions are required to differentiate FX(-/F) mice from
FX(F/F) mice.  (A) BanI digest of the 350-bp exon 8 PCR product clearly identifies the
FX(+/F) genotype (lane 3); however, it does not differentiate between the FX(-/F) and
FX(F/F) genotypes (lanes 1 and 2).  (B) Presence of a 600-bp PCR product amplified
across a Neo/ΔHPRT sequence (Figure 19A) reveals the FX(-/F) genotype (lane1) and
its absence indicates the FX(F/F) genotype (lane2).
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3.3.3  Southern blot results
In a Southern hybridization with a 2.8-kb FX probe (Figure 19C), EcoRV
digested DNA from correctly targeted HAT-resistant ES clones (previously
identified by two separate PCR reactions) yielded a single 4.7-kb fragment
(Figure 22, lanes 1-7) that is indistinguishable from a wild-type fragment (Figure
22, lane 8, lower band); EcoRV digested DNA from an heterozygous FX(+/-) ES
clone was included as a marker control (Figure 22, lane 8).   When hybridized
with the same FX probe, EcoRV digested genomic DNA from mice [FX(F/F),
FX(+/F), and FX(+/-)] revealed the same results (data not shown).
Figure 22. Southern blot analysis of DNA from HAT-resistant ES clones.
DNA from HAT-resistant ES clones previously identified by PCR analysis were
digested with EcoRV and hybridized with a 2.8-kb FX probe (Figure 19C).  DNA from
correctly knock-in clones yielded a 4.7-kb fragment (lanes 1-7) that is indistinguishable
from a wild-type fragment (lane 8, lower band).  EcoRV digested DNA from an
heterozygous FX(+/-) ES clone resulting from the first targeting event was included as
a marker control (lane 8).
3.3.4  Targeting frequency in the knock-in experiment
Electroporation of the FX plug-targeting construct to reconstitute the HPRT
minigene for HAT selection resulted in a high targeting frequency of correctly
retargeted ES cells.  Among the 48 HAT-resistant ES clones isolated for further
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analysis, 9 demonstrated correct targeting by both PCR and Southern
hybridization (shown in Figure 22 are 7 of 9 correctly knock-in ES clones).  Note
that while 19% of ES clones analyzed after the second retargeting event were
correctly targeted, only 4% of ES clones from the first, original targeting event
were correctly targeted; note this increase is greater than four-fold.
3.3.5  DNA sequencing results
Dideoxynucleotide sequencing of a 350-bp exon 8 PCR product amplified from
DNA samples of either HAT-resistant ES clones or of mice resulting from
mating of heterozygous FX(+/F) parents confirmed the correct base substitution
of TCC for CCC in exon 8.  Shown in Figure 23 are the sequencing results of
exon 8 PCR products derived from FX(+/F), and FX(F/F) mice, respectively.
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Figure 23. Sequencing analysis of PCR products. DNA Sequencing results of a
350-bp exon 8 PCR product confirm the correct base substitution of TCC for CCC in
one allele of FX (+/F) mice (upper panel) and in both alleles of FX(F/F) mice (lower
panel).
3.3.6  Production of homozygous FX(F/F) mice
One heterozygous FX(+/F) ES clone identified by PCR and Southern
hybridization and confirmed by DNA sequencing was used to generate chimeric
mice.  After mating with C57/BL6 females, chimeric males transmitted the FX-
Friuli allele to approximately half of their F1 offspring (n=24).  Heterozygous
FX(+/F) mice were intercrossed to generate homozygous FX(F/F) mice.  The
results of the intercross of FX(+/F) mice are highly informative and are
summarized in Table 6.  Representing 22% of the total progeny (n=298; p>0.2),
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FX(F/F) mice were born at the expected frequency based on Mendelian
inheritance.  Unlike FX(-/-) neonates, FX(F/F) newborn mice showed no
indication of any hemorrhagic condition.  Furthermore, FX(F/F) mice have
demonstrated normal survival; 80% of FX(F/F) mice have survived for at least
18 months whereas 100% of FX(-/-) mice have succumbed within 4 days.
Taken together, these results show that expression of the Friuli variant is
capable of rescuing FX knock-out mice from both embryonic and perinatal
lethality.  FX(F/F) mice (males and females) were also evaluated for their
reproductive fitness; no discrepancies with wild-type mice were noted in terms
of the frequencies of pregnancy and average size of littermates.
Table 6. Genotype distribution among offspring from heterozygous FX(+/F)
intercross.
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3.3.7  Levels of FX antigen in FX(F/F) mice
In Western blot analysis of two different dilutions of plasma (1:5 and 1:20),
FX(F/F) mice demonstrated levels of FX antigen similar to that shown by
FX(+/+) mice (Figure 24).
Figure 24. Western blot analysis of plasma.  Homozygous FX (F/F) mice
demonstrate levels of FX antigen similar to those shown by wild-type mice.  Western
blot analysis was performed at two different dilutions (1:5 and 1:20) to demonstrate
similar FX antigen levels in FX (F/F) and FX (+/+) mice.
3.3.8  Levels of FX activity in FX(F/F) mice
Using clotting assays, levels of FX activity in FX(F/F) mice were measured
(Table 7).  While FX(+/F) mice showed levels of FX activity approximately half
of those determined in wild-type mice (defined as 100%), FX(F/F) mice
revealed FX activity levels of 5.5 ± 1.8% in an aPTT-based assay and 5.5 ±
1.9% in  a PT-based assay. Thus, mouse model of FX-Friuli expresses levels of
FX activity representative of those shown by humans carrying the analogous
mutation.
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Table 7. FX coagulation activity in FX(+/+) , FX(+/F) and FX(F/F) adult mice.
Levels of FX activity are expressed in % normal.  Level of FX activity from FX(+/+)
mice was determined from pooled plasma (n=9).
3.3.9  Generation of FX(-/F) mice
Though useful and instructive as a viable model for FX deficiency, homozygous
FX(F/F) mice nevertheless failed to define a lower limit of FX activity or FX
antigen essential for survival, since these mice exhibited normal embryonic and
postnatal survival.  In order to generate and characterize mice with even lower
levels of FX activity and antigen, FX(F/F) females were crossed with FX(+/-)
males.  Two different genotypes [FX(+/F) and FX(-/F)] were expected in the
offspring of this cross.  Genotype analysis of 97 offspring from such a mating
revealed the expected distributions with 54% FX(+/F) and 46%
FX(-/F) mice (p>0.2) (Table 8).  Postnatal survival of FX(-/F) mice has also
been normal with 80% of FX(-/F) mice surviving for longer than 15 months.
FX(-/F) mice are reproductively competent with frequencies of pregnancy
comparable to those exhibited by wild-type mice (data not shown).
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Table 8. Genotype distribution in offspring resulting from cross of FX(F/F)
females and FX(+/-) males.
3.3.10  Levels of FX activity in FX(-/F) mice
Recall no FX antigen was observed in FX knock-out mice and levels of FX
antigen in homozygous FX(F/F) mice were similar to that of wild-type mice as
determined by a series of Western blot analyses.   Based on those
observations, it was therefore expected that FX(-/F) mice would likely have
levels of FX antigen approximately half of those in FX(F/F) mice (with protein
synthesized only from the Friuli allele, but not from the knock-out allele in
FX(-/F) mice).  Next, FX activity of the FX(-/F) genotype was investigated. To
determine levels of FX activity in FX(-/F) mice, aPTT and PT clotting assays
were performed; FX(-/F) mice showed FX activity levels of 1.1 ± 0.1% in an
aPTT-based assay and 2.9 ± 0.2% in a PT-based assay (Table 9).  Based on
these results, it can be concluded that FX activity levels of 1-3 % and FX
antigen levels (~50%) are still adequate to rescue both embryonic and perinatal
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lethality of FX knock-out mice showing complete absence of FX activity and
antigen.
Table 9. FX Coagulation activity in FX(-/F) mice and age-matched wild-type adult
mice.  Levels of FX activity are expressed in % normal.  Level of FX activity from
FX(+/+) mice was determined from pooled plasma (n=9).
3.3.11  Genotypic analysis of the offspring from FX(-/F) intercross
FX(-/F) mice with 1-3% FX activity and ~50% FX antigen levels were
intercrossed to examine the genotypic representations of their offspring.  Based
on the results of the heterozygous FX(+/-) intercross (Table 2), no more than
12% of full-term progeny from FX(-/F) intercross are expected to be FX knock-
out mice.  However, genotype analysis of 89 full-term offspring resulting from
the FX(-/F) intercross revealed that FX knock-out mice are represented at even
further reduced proportion.  Whereas 12% of progeny from the heterozygous
FX(+/-) intercross were identified as FX(-/-) mice (Table 2), only 2% of progeny
resulting from the FX(-/F) intercross were FX(-/-) mice (Table 10).  Indicated by
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the p value of less than 0.001, the observed 2% FX knock-out mice from the
FX(-/F) intercross is statistically different from the expected 25% (Mendelian
frequency).
Table 10.  Genotype distribution among offspring from FX(-/F) intercross.
3.3.12  Phenotypic analysis of embryos from FX(-/F) mothers
Embryonic phenotypes of FX-deficient offspring resulting from mating of
FX(-/F) females and FX(+/-) males were characterized.   Several anomalies
were observed.  First, gross examination of uterine horns derived from low FX
mothers [FX(-/F) mothers with 1-3% FX activity and ~50% FX antigen] carrying
E10.5,  E11.5 or E12.5 embryos disclosed blood pools throughout the uteri
(Figures 25A, D and G).  The noted blood pools within uteri are likely maternal
in origin based on several observations:  1) they are found outside the yolk sacs
and in spaces between embryos; 2) no correlation was found between location
of blood pools and specific genotype of embryos; 3) the overall volume of blood
pools was far too great to be lost by a few FX(-/-) embryos in each litter.  Based
on the earlier results (Table 10), in which FX(-/F) mice were shown to survive
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embryonic development in expected Mendelian frequency, FX(-/F) embryos are
not expected to make any significant contribution, if at all, to the accumulation
of blood pools observed in the uteri of low FX mothers.  Second, the yolk sacs
of E10.5, E11.5, and E12.5 FX knock-out embryos were completely lacking in
visible vasculature and exhibited a rough, granular surface (Figure 25B, E and
H); these observations were not noted for the yolk sacs of other genotypes (in
the same E10.5, E11.5, and E12.5 litters) including the yolks sacs of FX(-/F)
embryos, which clearly show a smooth, vascularized surface (Figures 25C, F
and I).  Third, in addition to demonstrating abnormalities in the yolk sac
vasculature, it is also important to note that the FX knock-out embryos
examined (E10.5, E11.5 and E12.5) have also reabsorbed or have begun to
reabsorb (Figures 25B, E and H).  Therefore, with these observations, the
relationship between cause and effect is unclear.
Next, FX(+/-) females (these females have ~50% FX activity and ~50 FX
antigen) were mated with FX(+/-) males.  However, examination of the uteri of
FX(+/-) mothers carrying E13.5 embryos did not reveal any evidence of blood
pools (Figure 26A).  This observation in FX(+/-) mothers provided an additional
support for the belief that blood pools in the uteri of FX(-/F) mothers are
maternal rather than embryonic in origin.  Examination of these E13.5 embryos
from FX(+/-) mothers (n=2) revealed one viable FX knock-out embryo (Figure
26B).  Unlike the FX knock-out embryos born to FX(-/F) mothers (Figures 25B,
E and H), this FX knock-out embryo born to FX(+/-) mother showed clearly
visible vasculature in its yolk sac (Figure 26B) and is indistinguishable from a
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wild-type littermate (Figure 26C).   This finding is not completely unexpected,
since approximately 50% of FX knock-out embryos have survived embryonic
development (Table 2).
Figure 25. Examination of E10.5, E11.5 and E12.5 FX-deficient littermates from
FX(-/F) mothers. During pregnancy, FX(-/F) mothers suffer severe but non-fatal
intrauterine hemorrhage (A, D and G).  While FX(-/F) embryos are viable and show
clearly visible vasculature in their yolk sacs (C, F and I), FX knock-out littermates have
reabsorbed and lack any vasculature in their yolk sacs (B, E and H).
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Figure 26. Examination of E13.5 FX-deficient littermates from a FX (+/-) mother.
(A) During pregnancy, FX(+/-) mothers do not suffer from intrauterine hemorrhage (i.e.
no blood pools are noted in the uteri of these mothers).  (B) A viable FX knock-out
embryo at E13.5 shows a clearly defined yolk sac vasculature that is indistinguishable
from that of a wild-type littermate (C).
3.3.13  Histological analysis of FX-deficient mice
The FX(F/F) and FX(-/F) mice, both of a mixed background, have demonstrated
normal survival through the postnatal period.  However, a previous report
documents that both low TF (~1%) and low FVII (~1%) mice exhibit cardiac
fibrosis resulting from recurrent episodes of hemorrhaging into the myocardium
from cardiac vessels.67   Examination of cardiac tissues from 10 months-old FX
(F/F) mice disclosed similar findings, i.e. Prussian blue staining revealed iron
depositions in the myocardium, and Masson’s trichrome staining also showed
fibrosis localized to the same areas (Figures 27E-H and Figures 28A-F).
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Cardiac tissue of the wild-type littermates examined at the same age did not
show evidence of iron deposition nor cardiac fibrosis (Figures 27A-D). These
findings are consistent with the observations made by Pawlinski and colleagues
in low TF and low FVII mice.67   Examination of FX(F/F) mice at 3 months of
age failed to disclose evidence of iron deposition and cardiac fibrosis (data not
shown).  Interestingly, two FX (-/F) mice (with 1-3% FX activity) examined at 7-
months of age did not show obvious signs of iron deposition or cardiac fibrosis
(Figures 27I-L).  Therefore, these results suggest that both genotype and age of
mice are important determinants in the development of cardiac fibrosis in FX-
deficient mice.  Serial tissue sections from spleens of FX-deficient mice and
wild-type littermates (10 months-old and 7 months-old) were also analyzed by
Prussian blue and Masson’s trichrome stains.  No noticeable differences were
detected by Masson’s trichrome staining (Figures 29B, D and F).  However, FX
deficient mice [both 10 months-old FX(F/F) mice and 7 months-old FX(-/F)
mice] showed elevated iron levels in their spleens (Figures 29A and C).
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Figure 27. Histologtical analysis of the heart tissues from FX deficient mice.  Iron
deposition and fibrosis were found in the heart tissue of a 10 months-old FX(F/F)
mouse (E-H), but not in that of a wild-type littermate examined at the same age (A-D).
Interestingly, neither iron deposits nor fibrosis were found in the heart tissue of a 7
months-old FX(-/F) mouse (I-L).
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Figure 28. Co-localization of iron deposits and fibrosis.  Further examination of the
cardiac tissue from a 10 months-old mice FX(F/F) mouse revealed that fibrosis (D-F)
had localized to the same areas as iron deposits (A-C).
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Figure 29. Histological analysis of the spleen tissues from FX-deficient mice.
While spleen tissue from a 10 months-old FX(+/+) mouse showed a normal level of iron
(E), the same tissue from both FX(F/F) and FX(-/F) mice (10 months-old and 7 months-
old, respectively) demonstrated abnormally high levels of irons (blue spots in A and C).
For all three genotypes examined, no obvious differences in fibrosis development were
noted (B, D and F)
3.4  Discussion
As demonstrated in the previous chapter, complete FX deficiency (i.e. no FX
catalytic activity and FX antigen) resulted in embryonic lethality of
approximately half of the expected numbers of FX knock-out mice and fatal
perinatal hemorrhage in the remaining half that survive to birth.  Thus, one of
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the highest priorities was to rescue FX knock-out mice from embryonic and
perinatal lethality.  Using the plug-and-socket sequential targeting strategy as
detailed above, the first viable mouse model of FX deficiency was generated.
Expression of the analogous mouse FX mutation was based on a naturally
occurring human FX variant (FX-Friuli).
Expression of FX-Friuli in mice successfully resulted in complete rescue
of the FX knock-out mice from both embryonic lethality and perinatal mortality.
While FX knock-out mice represented only 12% of the full-term progeny
resulting from the heterozygous FX(+/-) intercross (Table 11), genotype
analysis of 298 full-term offspring resulting from the intercross of the
heterozygous FX(+/F) mice identified 64 or 22% homozygous FX(F/F) mice
(Table 11).  The percentage of homozygous FX(F/F) mice is not statistically
different from the expected 25% (p>0.2) in the absence of embryonic lethality,
thus suggesting embryonic success of FX(F/F) mice.  Unlike the FX knock-out
mice that developed to term, FX(F/F) newborn mice did not show or develop
any visible signs of hemorrhagic conditions and were indistinguishable in
appearance from their wild-type littermates.  The postnatal survival of
homozygous FX(F/F) mice is also remarkable with 80% of these mice living
longer than 18 months, whereas the survival of 26 FX knock-out mice
developing to term was limited to 4 days (Table 11).
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Table 11. Comparison of FX(+/-) intercross and FX(+/F) intercross.
Detailed analysis of homozygous FX(F/F) mice revealed characteristics
that mirror those exhibited by individuals homozygous for the analogous FX
mutation.  As reported for humans, mice expressing the FX Friuli variant also
demonstrated 4-8% FX activity (as determined by both aPTT and PT clotting
assays) and normal FX antigen levels (as judged by Western blot analysis).
These similarities are not completely unexpected in light of the knowledge that
the Friuli mutation occurs in a particular amino acid residue that is highly
conserved among several species including human and mouse.   Nevertheless,
by the virtue of a viable FX-deficient mouse model with a set of specific
characteristics, it is learned that expression of a FX variant with as low as 4-8%
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FX activity and normal antigen level is readily able to support both embryonic
and postnatal survival.
In an attempt to determine the lower limit of FX activity and FX antigen
levels required to support embryonic and postnatal survival, FX(F/F) females
were mated with FX(+/-) males to produce FX(+/F) and FX(-/F) offspring; the
latter genotype is expected to generate FX-deficient mice associated with even
lower FX activity and FX antigen levels than those shown by FX(F/F) mice.
Genotype analysis of 97 full-term progeny resulting from such a mating
identified 46% FX(-/F) mice (Table 8).   No statistical difference was found
between the observed representations of FX(-/F) mice (46%) and the expected
representations (50%) in complete absence of embryonic lethality (p>0.2).  This
result suggests an absence of significant embryonic lethality in FX(-/F) mice.
Despite the still lower FX activity and FX antigen levels, FX(-/F) mice
demonstrated relatively normal postnatal survival; 80% of FX(-/F) mice have
survived at least 15 months (note the average lifespan of mice is 24 months).
While Western blot analysis of plasma from FX(-/F) mice was not performed,
the relative levels of FX antigen in FX(-/F) mice are expected to be
approximately half (~50%) of those in homozygous FX(F/F) mice, which
demonstrate FX antigen levels similar to those in wild-type mice.  Indeed,
FX(-/F) mice present even lower FX activity (1-3%) compared to 4-8% in
homozygous FX(F/F) mice (Tables 9 and 7).  Taken together, these results
suggest that while complete absence of FX activity and FX antigen is
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incompatible with life, 1% FX activity and 50% FX antigen levels are
nonetheless adequate to rescue both embryonic and perinatal mortality in
FX knock-out mice.   Furthermore, survival of mice at 1-3% FX activity is similar
to observations made in humans, thus confirming utility of these low FX mice as
model for human bleeding disorder.  Due to normal embryonic and postnatal
survival of FX(-/F) mice with 1-3% FX activity and 50% antigen levels,
expression and characterization of a FX variant with less than 1% FX activity
and antigen level (eg. FX-Stuart, see Table 5) may be necessary to unveil the
lower limit of FX required for survival.68,69
 It is important to note that although both FX(F/F) and FX(-/F) mice have
overcome embryonic and postnatal lethality, they are not completely normal
compared to wild-type mice.  First, 10 months-old FX(F/F) mice have developed
cardiac fibrosis, contributed by both genotype and age (Figure 28).  All FX-
deficient [FX(F/F) and FX(-/F)] mice examined demonstrated significantly
elevated levels of iron in their spleen tissues (Figure 29).  Though not fatal,
severe intrauterine hemorrhage is also observed in FX(-/F) mothers during
pregnancy (Figure 25).
From the previous chapter, it was demonstrated that complete FX
deficiency (complete absence of any FX catalytic activity and FX antigen)
resulted in partial embryonic lethality and fatal perinatal bleeding.   These
observations give rise to the following questions.  Why did partial embryonic
lethality occur in place of complete embryonic lethality?  Why was
developmental success observed in some FX knock-out mice, but not in
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others?   Although several hypotheses have been described to explain partial
embryonic lethality observed in some knock-out mouse models, including FV,
FII (prothrombin), and FX knock-outs, no evidence has been provided to
confirm any of the proposed hypotheses.  Based on the data that approximately
50% of FX knock-out mice developed and survived to term, it seems that the
embryonic requirement for FX is not absolute.  On the other hand, the
remaining 50% of FX knock-out mice failed to complete development; this
would on the contrary suggest that embryonic requirement for FX is essential.
One of the hypotheses offered to elucidate incomplete embryonic block
describes the role of maternal transfer of some clotting factors during
development.
FX(-/F) mice provided a rare opportunity to evaluate the contribution of
maternal FX to embryonic survival of FX knock-out mice.  It enabled a
comparison of the FX(-/F) intercross with the FX(+/-) intercross; it specifically
allowed for direct comparison of FX knock-out offspring resulting from FX(-/F)
mothers (with 1-3% FX activity and ~50% FX antigen levels) with those
resulting from FX(+/-) mothers (with ~50% FX activity and ~50% antigen levels).
While genotype analysis of 213 full-term offspring from FX(+/-) intercross
identified 12% FX(-/-) mice, the same analysis of 89 full-term offspring resulting
from FX(-/F) intercross revealed only 2% FX(-/-) mice (Table 12).  A statistical
analysis (i.e. Fisher’s exact test) confirms that 2% FX knock-out mice in the
FX(-/F) intercross is significantly different from the 12% FX-null mice in the
FX(+/-) intercross (p=0.0045).
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Table 12. Comparison of FX(+/-) intercross and FX(-/F) intercross.
A detailed comparison of these two intercrosses focusing specifically on
the relationship between levels of FX activity in mothers and representation of
FX knock-out mice at birth reveals insights and implications that were not
previously possible with other crosses.   First, the comparison shows an
apparent correlation between levels of FX activity in mothers and representation
of full-term FX knock-out mice with decreased levels of maternal FX activity
resulting in increased embryonic lethality of FX(-/-) mice and thus their reduced
representation at birth.  Although the observed correlation between FX activity
in mothers and representation of FX knock-out mice at birth can be attributed to
variations in the mixed genetic backgrounds of mice used in the study (i.e. FX-
deficient mice were not bred on a single, pure genetic background), results
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summarized in Table 12 are nonetheless consistent with the hypothesis of
maternal transfer of FX during embryonic development.
Taken together, these findings suggest that 1) there is a maternal
transfer of FX during development; 2) the maternal contribution of FX is
perhaps variable (levels of maternal FX activity represent the limiting factor); 3)
maternal FX supports embryonic survival of FX knock-out mice.  Furthermore, if
the hypothesis of maternal transfer is indeed correct, it can then be concluded
that partial embryonic lethality of FX(-/-) mice may be due to variable  transfer of
maternal FX adequate to support embryonic survival of some but not all FX-
knock-out mice, and moreover that the embryonic requirement for FX is
essential, evident in reduced maternal FX levels resulting in increased
embryonic lethality of FX knock-out mice.
Second, the comparison of two intercrosses described above also
reveals additional insight for determining whether it was the restoration of
minimal FX catalytic activity or of FX antigen that enabled rescue of FX
knockout mice from embryonic lethality.  As shown earlier, FX knock-out mice
did not show any FX activity or FX antigen.  Expression of FX-Friuli with 4-8%
FX activity and normal FX antigen levels was able to achieve complete rescue
of FX knock-out mice from embryonic and perinatal lethality.  While it is thought
that catalytic function of FX is essential for perinatal survival, it is unclear
whether catalytic activity of FX protein is required for embryonic survival.
[Some studies have suggested that FX/FXa have the ability to induce biological
responses in the absence of its catalytic activity].52-54   In other words, are FX
85
mice able to survive embryonic development on a catalytically inactive FX
protein?  Comparison of the two intercrosses above [FX(-/F) intercross and
FX(+/-) intercross] (Table 12) suggests that embryonic survival of FX mice on a
catalytically inactive FX protein is unlikely.   While FX(-/F) and FX(+/-) mothers
demonstrated distinct levels of FX activity (1-3% and ~50% respectively), they
actually shared similar levels of FX antigen (~50%; FX protein synthesis is
absent from the knock-out allele, but present at similar levels for the Friuli and
wild-type alleles as demonstrated in Western blot analysis).  Therefore, if the
hypothesis of maternal transfer of FX is correct, an inference can be drawn;
reduced representation of full-term FX knock-out mice (2% of total progeny)
from FX(-/F) mothers compared to 12% full-term FX knock-out mice from
 FX(+/-) mothers is due to maternal transfer of reduced FX activity rather than of
FX antigen (since FX(-/F) and FX(+/-) mothers have similar levels of FX antigen
but distinct levels of FX activity).  Furthermore, one can conclude that it was the
restoration of minimal FX catalytic activity (not of FX antigen) with the
expression of homozygous FX-Friuli that rescues FX knock-out mice from
lethality.
Based on the conclusions made here, the following prediction is made.  It
can be hypothesized that an intercross of specific heterozygous FX mice (mice
with one wild-type FX allele and one mutated FX allele; the second allele results
in normal synthesis of catalytically inactive FX protein) should produce
homozygous FX mutated mice that behave virtually as FX Knock-out mice in
terms of their representations at birth (12%).  Despite synthesizing normal
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levels of FX antigen, these homozygous mice like FX knock-out mice will not
have any FX catalytic activity, which was suggested earlier to be essential for
embryonic survival.   For these homozygous FX-mutated embryos, the only
source of catalytically active FX protein will be the mothers (~50% FX activity)
as it was for FX knock-out embryos resulting from FX(+/-) mothers (also ~50%
FX activity).
Third, while relative embryonic survival of FX knock-out mice is directly
dependent on the specific genotype of the mother (with specific levels of
maternal FX activity), the embryonic success of FX(-/F) mice is completely
independent of the mother’s genotype.  For instance, in both FX(F/F) X FX(+/-)
cross and FX(-/F) intercross, FX(-/F) mice were born at expected frequencies
with absence of embryonic lethality.  Therefore, endogenous FX activity as low
as 1% (shown by the FX(-/F) genotype) is sufficient to support both embryonic
and postnatal survival, regardless of mother’s genotype [FX(+/-), FX(+/F),
FX(F/F), or FX(-/F)].
The underlying cause of embryonic lethality of FX knock-out mice is still
unclear.  Recall examination of yolk sacs of E10.5, E11.5 and E12.5 FX knock-
out embryos from FX(-/F) mothers revealed complete absence of vasculature
(Figure 25B, E and H), whereas normal vasculature development was clearly
observed in the yolk sacs of FX(-/F) embryos respectively from the same litters
(Figure 25C, F and I).  At the same time, inspection of the FX knock-out
embryos themselves also revealed that they have already reabsorbed or have
begun to reabsorb.  One hypothetical explanation may be that FX is either
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directly or indirectly involved with the proper formation and/or development of
vasculature in the yolk sac, and consequently in the absence of FX-related
function, development of the yolk sac vasculature is impaired, leading to re-
absorption and thus embryonic lethality of FX knock-out mice.  Alternatively, it
may be the death of FX knock-out embryo that leads to the observed
abnormalities in the yolk sac vasculature.  At this point, it is unclear which event
occurs first or simultaneously.   At the same time, it is important to note that
FX transcript has been detected in both embryo and yolk sac as early as E7.5
in development.55
Still a point of uncertainty is whether embryonic lethality and perinatal
mortality share the same underlying cause.  While failure to generate thrombin
has been thought to be the cause of perinatal lethality in FX-knock-out mice, the
underlying cause of embryonic lethality remains to be deciphered.   In other
words, it is unclear whether embryonic failure and perinatal mortality can be
attributed to absence of a single function of FX; does FX have two distinct roles
in development and postnatal survival?
In summary, the data presented in this chapter suggest that FX
(catalytically active FX) is required for embryonic survival, whether it is
embryonic or maternal in origin.  If the FX source is embryonic, FX activity as
low as 1% [as in FX(-/F) mice] is sufficient to support both embryonic and
postnatal survival independent of the mother’s genotype.  However, if the only
FX source is maternal as it is for FX knock-out embryos, the likelihood of
embryonic survival of these mice is directly dependent on the specific genotype
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of the mother. Reduced levels of maternal FX activity result in decreased
embryonic survival of FX knock-out mice and their decreased representation at
birth.  Although these findings and observations do not define a specific
developmental role for FX (as demonstration of its requirement does not
necessarily reveal its essential function), they do support a role of maternal FX
in embryonic success of FX knock-out embryos.  Moreover, the data suggest
that the maternal transfer of FX is perhaps variable (i.e. variable in distribution),
sufficient to support embryonic survival of some but not all FX knock-out mice.
Perhaps, it was variable transfer of maternal FX that results in partial embryonic
lethality of FX-null mice.  In light of data presented here, it is likely that partial
embryonic lethality also observed in both FV and FII (prothrombin) knock-outs
is due to limited maternal transfer of the respective hemostatic factors.
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4. FX expression during development
4.1 Introduction
In contrast to other vitamin K-dependent clotting factors, FVII and FIX, which
are expressed solely in liver, FX is expressed predominantly, but not exclusively
in liver.47,70   Northern blot analysis of adult human tissues revealed FX mRNA
in various tissues in addition to liver.47   Functional study of the 5’ flanking
region of human FX gene revealed an interaction of a regulatory sequence
(CCAAT) with an ubiquitous transcription factor, NF-Y.47   Though the same
regulatory sequence is found in the 5’ flanking region of FIX gene, it interacts
with a transcription factor, NF-1 that is structurally unrelated to the ubiquitously
expressed NF-Y transcription factor.71,72   These observations may explain why
FX is expressed in multiple tissues whereas expression of FIX is confined to
liver.  RT-PCR analysis of some cell lines derived from the central nervous
system (human glioblastoma and human neuroblastoma) also demonstrated FX
mRNA in those cells.73
Additionally, RT-PCR analysis of RNA from various tissues of adult
mouse showed FX transcript in multiple tissues including liver, stomach,
intestine, kidney, skeletal muscle, ovary, testes, and spleen.74   Though not
identical, tissue distribution of FX expression in adult mouse is similar to that in
adult human.47   Despite what has been learned about the tissue distribution of
FX in adult mouse, little is known about the embryonic expression pattern of FX.
As a matter of fact, to date, spatial and temporal patterns of FX expression
during mouse development have yet to be characterized.  On the other hand,
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characterization of various chick embryonic tissues at E13 revealed FX mRNA
of various levels in liver, chorioallantois, allantoamnion, kidney, spleen, and
intestine.75  In light of this finding in chick embryonic tissues, it is of interest to
determine whether FX expression during murine development is also observed
in multiple tissues.
Thus far, the underlying cause of embryonic lethality of FX knock-out
mice is still unclear.  Could embryonic lethality observed in FX knock-out mice
be attributed to a function of FX/FXa that is independent of its role in thrombin
generation in blood coagulation?  A previous study on embryonic expression of
murine coagulation system components has reported early expression of some
hemostasis-related genes (including FX) prior to the formation of a functional
circulatory system.55   This finding supports the concept that some coagulation
factors may have additional non-hemostatic functions during development.
Temporal and spatial delineation of FX expression may provide some clues to
its function(s) during development.   For example, a comparative analysis of the
embryonic expression pattern of FX with that of a similarly expressed biological
molecule (i.e. cellular receptor) may reveal developmentally crucial interactions
that were previously overlooked.  Furthermore, identification of FX expression in
specific embryonic tissues may provide important knowledge to design an
alternative rescue strategy for FX knock-out mice (i.e. tissue-specific rescue of
FX knock-out mice).   Therefore, the primary objective of the study presented in
this chapter is to gain some insight into the embryonic pattern of murine FX
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expression by carrying out both in situ hybridization and immunohistochemical
study.
4.2  Materials and methods
4.2.1  Timed mating of heterozygous FX(+/-) mice
Conception was determined by observation of a coital plug.  At various stages
of embryonic development (e.g. E9, E10.5, E11.5, E12.5, E13.5, E14.5, and
E15.5), pregnant females were sacrificed, and only viable (non-reabsorbed)
embryos were harvested, fixed in 4% paraformaldehyde, and further processed
for either in situ hybridization of whole mount embryos or of paraffin-embedded
embryo sections (depending on the embryonic age). To prevent any
discrepancy in treatment of samples, genotype of viable embryos was
determined only after each hybridization experiment, using yolk sac DNA.
Attempt to genotype reabsorbed embryos was also made; in DNA samples that
were not yet completely degraded at the time of isolation, FX-knock-out
genotype was recovered at greater than 90% frequency.  Reabsorbed embryos
were not treated for in situ hybridization because of degraded transcript.
4.2.2  Synthesis of FX riboprobes
Mouse FX cDNA (~1.1-kb) corresponding to exons 1 to 7 and FX cDNA (~340-
bp) corresponding to exon 8 were cloned separately into a transcription vector
(pBluescript II SK(+/-); Stratagene) at EcoRI / EcoRV sites and EcoRV / HincII
sites, respectively.  Before in vitro transcription using the DIG-labeling kit
(Roche), two DNA templates were linearized by digestion with EcoRI or EcoRV,
respectively.   Following separate in vitro transcription reactions with
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Digoxigenin-UTP and RNA polymerase T7, two Digoxigenin-labeled antisense
FX RNA (ribo) probes were generated; a 1.1-kb anti-sense FX riboprobe and a
340-b anti-sense FX riboprobe.  To generate the sense probes, two DNA
templates were digested with EcoRV or DraII, respectively.  Two separate in
vitro transcription reactions were carried out using RNA polymerase T3 to
generate the corresponding Digoxigenin-labeled sense FX riboprobes.
4.2.3  Whole-mount in situ hybridization (E9 to E12.5)
In situ hybridizations of whole-mount embryos were carried out based on a
protocol (kindly provided by Dr. J. Golden, University of Pennsylvania).  After
re-hydration, embryos were bleached with 6% hydrogen peroxide, treated with
10 µg/ml proteinase K for 20 minutes, and washed with 2 mg/ml glycine solution
for 10 minutes.  Following post-fixation for 20 minutes with 4%
paraformaldehyde and 0.2% glutaraldehyde solution, embryos were incubated
in pre-hybridization solution (50% deionized formamide, 5x SSC (pH 4.5), 1%
SDS, 50 µg/ml heparin, 50 µg/ml yeast RNA) for 1 hour at 70°C, and then in
hybridization solution containing either the 1.1-kb anti-sense FX riboprobe or
the 340-b anti-sense FX riboprobe (1 µg/ml) at 70°C overnight.   After several
washes, embryos were blocked with blocking solution (10% heated inactivated
sheep serum, 2% blocking reagent, Roche, and 2 mM levamisole) for 2 hours,
and incubated overnight at 4°C with 1:2000 pre-absorbed sheep anti-DIG,
alkaline phosphatase conjugated Fab (Roche cat# 1093274) in solution
containing 1% heat inactivated sheep serum, 2% blocking reagent (Roche), and
2 mM levamisole in TBST (50 mM Tris-Hcl, pH7.5, 150 mM NaCl, 10 mM KCl,
93
and 0.1% Tween 20).   After washes with TBST, embryos were washed 3x for
10 minutes each with NTMT (100 mM NaCl, 100 mM Tris, pH 9.5, 50 mM
MgCl2, 0.1% Tween, and 2 mM levamisole), and then incubated with BM purple
(Roche) in darkness until sufficient signal intensity was developed (usually
overnight at 4°C).  After sufficient color development, embryos were washed 2x
for 10 minutes each with NTMT and 2x for 10 minutes each in PBT (PBS,
pH5.5, 0.1% Tween 20), post-fixed with 4% paraformaldehyde, 0.1%
glutaraldehyde in PBS for one hour at room temperature, further washed with
PBT, and stored in PBT at 4°C until further microscopic analysis.  When
available, knock-out embryos were included in the same analysis.   For other
negative controls, corresponding DIG-labeled sense FX riboprobe was used in
place of an anti-sense FX riboprobe.
4.2.4  In situ hybridization of paraffin-embedded embryo tissue sections
(E13.5 to E15.5)
With some additions, the following protocol was also based on a protocol (kindly
provided by Dr. J. Golden).  To carry out in situ hybridizations of paraffin-
embedded embryo tissue sections, sections were dewaxed in xylene and
treated in a graded series of methanol/PBT solutions (from 100% methanol to
25% methanol/PBT).  After wash in DEPC-treated PBS, sections were fixed in
4% paraformaldehyde (pH7.2) for 20 minutes.  After additional wash in DEPC-
treated PBS, sections were treated with 10 µg/ml proteinase K in PBS (for 5-20
minutes depending on the age of embryo section).  Following proteinase K
treatment and PBS wash, tissue sections were post-fixed with 4%
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paraformaldehyde (pH7.2) for 15 minutes.  Following additional washes in
DEPC-treated PBS, sections were acetylated; sections were incubated 2 x 5
minutes in 0.1 M triethanolamine (TEA) buffer, pH8.0 containing 0.25% (v/v)
acetic anhydride (Sigma) in Coplin jars, which were rocked vigorously.
Subsequently, sections were covered in pre-hybridization mix (50% deionized
formamide, 5X SSC, 2% blocking powder (Roche), 0.1% Triton X-100, 0.1%
CHAPS (Sigma), 1 mg/ml tRNA, 5 mM EDTA, and 50 µg/ml heparin).  Before
pre-hybridization, tissue sections were covered with a piece of parafilm, placed
in a box containing tissue paper soaked in 50% formamide and 5X SSC, and
incubated for one hour at 70°C.  Next, sections were incubated with
hybridization mix containing either the 1.1-kb DIG-labeled anti-sense FX
riboprobe or the 340-b DIG-labeled anti-sense FX riboprobe (650 ng/ml) in 70°C
overnight.  Following overnight hybridization, slides were washed 3x for 15
minutes each in a solution (50% formamide, 5% SSC (pH4.5, 1% SDS) at 70°C,
then 3x for 15 minutes each in another solution (50% formamide, 2X SSC,
pH4.5) at 65°C, and then 3x for 5 minutes each in TBST at room temperature.
Next, slides were blocked in 10% heat inactivated sheep serum/TBST for 30
minutes and incubated with a Sheep anti-DIG alkaline phosphatase conjugated
Fab (Roche; 1:2000) in the blocking solution at 4°C overnight.  Subsequently,
slides were washed with TBST 3x for 10 minutes each and with NTMT 3x for 5
minutes each.  For color development, slides were incubated in BM purple in
darkness.  When sufficient signal developed, color reaction was stopped by
washing slides in PBT (pH5.5).  After the wash, slides were dehydrated, cleared
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with xylene, mounted in Permount and coversliped before further analysis.
When available, tissue sections from FX knock-out embryos were included in
the same analysis.  For other negative controls, corresponding DIG-labeled
sense FX riboprobe was used in place of an anti-sense FX riboprobe.
4.2.5  Immunohistochemical staining for FX antigen
The protocol used for immunohistochemical studies of FX protein expression
was based on that provided by Vector Laboratories (Burlingame, CA).  Paraffin-
embedded embryo tissue sections were cleared in xylene and hydrated in a
series of decreasing concentrations of alcohol solutions.  Following the
manufacturer’s instructions to unmask antigen, slides were boiled in diluted
antigen unmasking solution (Vector laboratories) for 1 minute.  Slides were
incubated with 0.3% hydrogen peroxide in ddH2O for 30 minutes to quench
possible endogenous peroxidase activity and washed in PBS.  To block the
sections, slides were treated with diluted normal blocking serum (1.5%.) for 30
minutes.  After the wash, sections were incubated with an adsorbed sheep anti-
human FX antibody (10 µg/ml; Cedarlane) for 30 minutes, washed in PBS, and
incubated with diluted biotinylated secondary antibody (Vectastain Elite ABC kit
with sheep IgG; Vector laboratories). To amplify signal, sections were incubated
with Vectastain Elite ABC reagent for 30 minutes before the color reaction.  To
develop color signal, sections were incubated with peroxidase substrate
solution (Vector NovaRED; Vector laboratories).   After staining, sections were
rinsed in ddH2O, cleared with xylene, and mounted with Vecta Mount (Vector
Laboratories) for further analysis.  When available, tissue sections from FX
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knock-out embryos were included in the same analysis.  Other negative control
included omission of the primary antibody in the staining procedure.
4.3  Results
4.3.1  Whole-mount in situ hybridization (E9 to E12.5)
Whole-mount in situ hybridization studies demonstrated FX mRNA in the
midsection of E9 and E10.5 wild-type embryos (Figures 30 and 31).
Examination of an older (E11.5) embryos (hybridized with the DIG-labeled anti-
sense FX 1.1-kb probe) yielded similar results; FX mRNA was detected in the
midsection of a wild-type embryo, but not in a knock-out littermate (Figure 32).
No other prominent staining was noted in either.   A comparison of a wild-type
E12.5 embryo with its FX knock-out littermate also revealed FX transcript in the
liver area of the wild-type embryo, but its absence in the knock-out embryo
(Figure 33).  This result is consistent with the use of DIG-labeled antisense FX
exon 8 riboprobe in the hybridization, demonstrating absence of a transcript
containing exon 8 in the knock-out embryo.  More detailed inspection of the
wild-type E12.5 embryo revealed a punctate staining pattern in liver.  This may
reflect areas of hepatocytes (positive staining) interspersed with blood forming
islands (negative staining for FX), since liver is still a major site of hematopoietic
activity at this stage of development.
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Figure 30.  Whole-mount in situ hybridization of E9 embryos.  E9 embryos were
hybridized with a DIG-labeled antisense FX 1.1-kb probe.  Note a hybridization signal
(boxed area) in wild-type E9 embryo (A) and absence of the same signal in a FX
knock-out littermate (B).
Figure 31. Whole-mount in situ hybridization of an E10.5 embryo.  A wild-type
E10.5 embryo was hybridized with a DIG-labeled antisense FX 1.1-kb probe.  Positive
signal was detected in the liver area. False-positive signals in other areas might due to
trapping of the probe.
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Figure 32. Whole-mount in situ hybridization of E11.5 embryos. Embryos were
hybridized with a DIG-labeled antisense FX 1.1-kb probe.  While a signal was observed
in the liver area of a wild-type embryo (A), it was not detected in the same area of a
FX knock-out littermate (B).
Figure 33. Whole-mount in situ hybridization of E12.5 embryos.  Embryos were
hybridized with a DIG-labeled antisense FX exon 8 probe. While a signal was observed
in the liver area of a wild-type embryo (A and C), Figure 33 (continued),
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it was not detected in the same area of a FX knock-out littermate (B and D).   In this
case, the signal is noted as a punctate staining pattern.
4.3.2  In situ hybridization of paraffin-embedded embryo tissue sections
(E13.5 to E15.5)
In situ hybridizations of E13.5 wild-type paraffin-embedded tissue sections
showed FX mRNA in liver when hybridized with the DIG-labeled anti-sense FX
exon 8 riboprobe (Figures 34A and C) and absence of FX mRNA in the same
tissues when hybridized with the corresponding sense riboprobe (Figures 34B
and D).  Tissue distribution of FX mRNA expression widened in further
developed embryos.  Examination of FX mRNA expression in E14.5 wild-type
tissue sections indicated FX transcript in various tissues (liver, lung, brain, and
kidney) after sections were hybridized with the DIG-labeled anti-sense FX 1.1-
kb riboprobe (Figures 35A, C, E and G).  However, when hybridized with the
corresponding sense probe, tissue sections from the same embryo failed to
demonstrate FX transcript in any of these tissues (Figures 35B, D, F and H).  In
situ hybridization of E15.5 wild-type tissue sections disclosed still further
expansion of FX expression; when hybridized with the DIG-labeled anti-sense
FX 1.1-kb riboprobe, embryo sections revealed FX transcript in multiple tissues
including liver, lung, dorsal root ganglia, thymus, and anterior aspect of brain
(Figure 36).  There was little or no hybridization signal in GI tract (Figure 36).
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Figure 34. In situ hybridization of E13.5 wild-type paraffin-embedded embryo
sections.  Sections were hybridized with either DIG-labeled anti-sense FX exon 8
probe or the sense probe.  Signal was detected in the liver of an embryo section
hybridized with an anti-sense probe (A and C).  No signal was observed in the liver of
an embryo sections hybridized with a sense probe (B and D).  No other prominent
hybridization signals were noted (A-D).
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Figure 35. In situ hybridization of E14.5 wild-type paraffin-embedded embryo
sections. Sections were hybridized with either DIG-labeled anti-sense FX 1.1-kb probe
or the sense probe.  FX signal was detected in multiple tissues when sections were
hybridized with an antis-sense probe (A, C, E and G).  No signal was noted in any
tissue when sections were hybridized with a sense probe (B, D, F and H).
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Figure 36. In situ hybridization of E15.5 wild-type paraffin-embedded embryo
sections.  Shown above are sections hybridized with a DIG-labeled anti-sense FX 1.1-
kb probe.  Hybridization signal was detected in multiple tissues including liver, dorsal
root ganglia, lung, thymus, and anterior part of brain.  Little or no signal was detected in
GI tract.
4.3.3  Immunohistochemical staining for FX antigen
In the immunohistochemical study, a polyclonal antibody raised against human
FX and showing cross-reactivity with mouse FX was adsorbed and used to
investigate FX expression during mouse development.  FX expression was
observed in multiple tissues with its expression detected in more tissue types in
the later stages of development than in an earlier stage.  At E12.5, FX
expression was noted not only in the liver, but also in the heart, and lung
(Figures 37A and B).  These findings are supported by the absence of FX
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expression in the corresponding tissues in a FX knock-out littermate (Figures
37C and D).   Although some background staining can be observed in the lung
of the E12.5 FX knock-out embryo, its intensity is minimal compared to the
strong signal intensity shown in the lung of a wild-type littermate.
Figure 37. FX expression in E12.5 embryos.  Paraffin-embedded sections from an
E12.5 wild-type embryo (A and B) and from its knock-out littermate (C and D) were
incubated with a adsorbed polyclonal sheep anti-human FX antibody.  While signals
were detected in wild-type tissues, no signal was observed in FX knock-out tissues.
At E14.5, FX expression widened to include expression in liver, lung,
gastrointestinal tract, kidney, adrenal gland, dorsal root ganglia, thymus, and
anterior aspect of brain (Figure 38).  At this stage of development, the stronger
staining for FX expression was located in liver, kidney, adrenal gland, dorsal
root ganglia, and anterior area of brain with moderate and weaker staining
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noted in thymus, lung, and gastrointestinal tract.  Interestingly, no FX
expression was detected in the heart as it was in E12.5 embryos.
Figure 38. FX expression in E14.5 embryos. At this stage of development, FX
expression was detected in multiple tissues in addition to liver.
At E15.5, FX expression persisted in all those tissues in which FX expression
was observed in E14.5 embryos (Figure 38).  Additionally, FX expression was
seen in neopallial cortex and trigeminal ganglion (Figure 39).  A weaker staining
in the heart of an E15.5 embryo might be a false-positive staining 1) as it was
absent in the left side of the same embryo, and 2) it was absent in the heart of
E14.5 embryos, which showed very similar tissue distribution of FX expression.
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Figure 39. FX expression in E15.5 embryos. Likewise, FX expression was detected
in multiple tissues in addition to liver.
4.4  Discussion
Although FX transcript is found in a number of adult tissues,74 little is known
about its spatial or temporal pattern of expression during mouse development.
The goal in this chapter is to investigate the embryonic expression pattern of FX
at the tissue level, using both in situ hybridization and immunohistochemistry.
During the early stages of mouse development (E9-E12.5), FX expression is
predominantly located in the abdominal region (i.e. liver) with no apparent
expression found in other tissues (Figures 30-33).   Separate in situ
hybridizations using the anti-sense FX 1.1-kb riboprobe or the anti-sense FX
106
exon 8 riboprobe indicated consistent absence of FX transcript in FX knock-out
embryos.  Taken together, these findings suggest the instability of exon 8-
deleted FX transcript synthesized in the knock-out embryos.
According to the results of in situ hybridizations, embryonic distribution of
the FX transcript directly correlates with the age of the embryo, with wider
tissue distribution of the FX transcript in older than younger embryos.   As
expected, expression of FX transcript in the area of liver persisted throughout
the duration of the embryonic ages examined (E9 to E15.5).  At E14.5, FX
transcript was also observed in kidney, lung, and certain areas of brain in
addition to its already noted expression in liver (Figure 35).  While expression of
FX transcript was not noticeable in the kidney of E15.5 embryos, it was
observed in other tissues including liver, lung, dorsal root gangalia, thymus, and
the anterior aspect of the brain.  Though not pinpointing the exact cell types
responsible for FX transcription, these findings nevertheless demonstrate that
FX expression is not confined to liver during development.
Some correlations were noted between in situ hybridization results and
the immunostaining results for FX expression during mouse development.  The
strongest correlations between the two studies occurred in the older embryos
(E14.5 and E15.5 embryos).   Fewer correlations were observed in the younger
E12.5 embryos.  These observed discrepancies could be due to different
abundance of the FX transcript in various developing tissues and to differences
in the sensitivity of the two assays.  The differential immunostaining pattern in
E12.5 embryos from that observed in in situ hybridization is not likely due to
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false-positive immunostaining considering the absence of the analogous
staining pattern in E12.5 FX knock-out tissues.
An alternative strategy to delineate FX expression during development
involves use of a previously described plug-and-socket targeting.  A different
FX plug construct containing a reporter gene (e.g. β-galactosidase or GFP)
fused in frame with FX exon 8 sequences could be introduced into the HPRT-
negative ES cells that were originally targeted by the FX socket construct.  For
example, determination of GFP expression pattern in heterozygous GFP
embryos of various embryonic ages should accordingly reveal the spatial and
temporal patterns of FX expression during development.
Understanding of the embryonic pattern of FX expression can be
potentially useful in designing an alternative strategy for rescue of FX knock-out
mice from embryonic lethality.   In other words, rather than restoring minimal
levels of FX activity as in the Friuli mice, is it possible to rescue FX knock-out
embryos with tissue-specific restoration of FX expression?  Is it possible to
rescue FX knock-out embryos with hepatic-restricted expression of FX?  In
other words, is FX expression from tissues other than liver required to sustain
embryonic development?  These questions can be answered with the
generation and subsequent breeding of two different mice to produce mice with
hepatic-restricted expression of FX.  To generate the first mouse, a FX plug
construct containing three stop codons (flanked by loxP sites) upstream of exon
8 of FX gene, is introduced into the FX-null ES cells.  Mice homozygous for the
stop codons in FX gene will have similar phenotypes as those of FX knock-out
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mice.  Only the heterozygous mice will be viable and can be used for breeding.
A second transgenic mouse expressing cre recombinase under the control of a
liver-specific promoter will be generated.  Crosses of these mice will ultimately
generate mice that are homozygous for hepatic-restricted expression of FX.
Homozygous mice can then be examined for their embryonic and postnatal
survival.  However, if hepatic-restricted expression of FX is insufficient to
support embryonic survival, additional transgenic mice expressing FX in specific
non-hepatic tissues can be generated and characterized.  The choice of the
specific non-hepatic tissue to attempt embryonic rescue will depend on the
understanding of the embryonic pattern of FX expression.
Whether FX has a developmental-related role in addition to its function in
thrombin generation remains to be elucidated.  However, several studies and
observations have together suggested a potential non-hemostatic role for FX.
First, in contrast to closely related coagulation factors such as FVII and FIX, FX
is expressed in multiple tissues in adult human, suggesting a likelihood of
multiple functions.47   RT-PCR analysis of adult mouse tissues has also
demonstrated FX transcript in multiple tissues in addition to liver.74   Other
evidence supporting a non-hemostatic role for FX includes detection of FX
transcript as early as E7.5 (i.e. prior to the formation of a functional circulatory
system).55   Still other studies have demonstrated the ability of FXa 1) to induce
mitogenic activity in vascular smooth muscle cells both in vitro and in vivo, 2) to
elicit enhanced release of endothelial cell mitogens independent of thrombin,
and 3) to induce up-regulation of the egr-1 transcription in human keratinocyte
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cell line.50,52,76,77   Taken together, these findings suggest that FX may have
biological role(s) other than thrombin generation that influence embryonic
development and survival.  Therefore, further understanding of the embryonic
distribution of FX expression may unveil additional clues about its potential
role(s) in mouse development.
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5. Summary and future directions
In summary, the work presented here has shown that a mouse model of
complete FX deficiency, constructed with a plug-and-socket targeting strategy,
resulted in partial embryonic lethality, with FX-null mice born at ~50% expected
number, and those surviving to term dying of bleeding complications within the
first few days of birth.  These findings and those of a previously described
mouse model of FX deficiency63 are consistent with data in humans in which
complete FX deficiency is lethal.  Timed matings suggested that embryonic
lethality had occurred as early as E10.5 or even earlier.  While the perinatal
lethality in FX knock-out mice appears to be due to defective hemostasis, the
exact cause of embryonic lethality is unclear, since it occurs in mid-gestation
well before formation of a fully functional coagulation system, and furthermore,
it occurs in the absence of obvious evidence for bleeding.
Expression of an analogous mouse mutation based on a naturally
occurring human FX variant, FX-Friuli resulted in complete rescue of FX knock-
out mice from both embryonic and perinatal lethality.  Homozygous FX-Friuli
mice FX(F/F) demonstrated a similar phenotype in terms of FX activity
(averaging 5.5% in mice and 4-9% in humans), antigen (~100%), and survival
as humans carrying the analogous mutation.  Cross of homozygous FX(F/F)
mice with heterozygous FX(+/-) mice produced FX(-/F) mice with even lower FX
activity (1-3%) and 50% antigen levels.  Normal survival of FX(-/F) mice
demonstrated that as low as 1% FX activity and 50% antigen levels are
nonetheless still sufficient to support both embryonic and postnatal survival.
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Moreover, survival of FX(-/F) mice at 1-3% FX activity is similar to observations
in humans, thus confirming utility of these mice as an accurate model for human
bleeding disorders.   
The value of FX(-/F) mice is not limited to their utility for studying and
developing novel treatments for FX deficiency.   FX(-/F) mice enable
investigation into an elusive role of FX during development by allowing for
examination of FX knock-out mice born to mothers with minimal levels of FX
activity.  In an important contrast to a viable FX knock-out embryo born to a
FX(+/-) mother with 50% FX activity and antigen levels (Figure 26), some FX
knock-out offspring of FX(-/F) mothers with 1-3% FX activity and 50% antigen
levels clearly lack yolk sac vasculature and have reabsorbed in the absence of
hemorrhage (Figure 25).  While the cause and effect relationship is unclear,
these observations are highly suggestive of an essential role of FX directly or
indirectly in development.
Furthermore, FX(-/F) mice provide an opportunity to assess contribution
of maternal FX to embryonic survival.  Comparison between FX(-/F) intercross
and FX(+/-) intercross suggests the following: 1) maternal transfer of FX or a
direct relationship between maternal levels of FX activity and embryonic
survival of FX knock-out mice with higher maternal levels of FX activity resulting
in a greater representation of FX knock-out mice at birth; 2) rescue of FX knock-
out mice from both embryonic and perinatal lethality is likely due to restoration
of FX catalytic activity and not due to establishment of FX antigen.
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Detection of the FX transcript in various tissues of adult mice also
supports a hypothesis of multiple FX functions.  Thus, coupled with other
findings on FX, a detailed delineation of the embryonic pattern of FX expression
may uncover additional clues to define the exact role of FX with relation to
embryonic development.
 At this point, several important questions about FX functions remain to
be addressed.  While complete FX deficiency is lethal and expression of a FX
variant [i.e.FX(-/F)] with 1-3% FX activity and/or 50% antigen levels is
compatible with life, the minimal characteristics of a FX molecule that are
required to support embryonic or postnatal survival remain to be demonstrated.
The utility of the plug-and-socket targeting strategy is that it will be possible to
separate the roles of antigen and activity in embryonic survival.  For example,
one can characterize the embryonic effects resulting from expression of an
active site mutation such as homozygous FX Stockton with no detectable
activity but normal antigen levels.57   Furthermore, one can evaluate the
embryonic effects of a human FX variant with less than 1% activity and
circulating antigen level (i.e. FX Stuart).68,69   Studies of these additional FX
variants should define those characteristics of a FX molecule that are minimally
required for embryonic development.  As a matter of fact, these studies are
already in progress.
Although the data presented in this study suggest maternal transfer of
FX during development and that relative embryonic success of FX knock-out
embryos depends on the maternal levels of FX activity, they are not absolutely
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final.  However, these results can be confirmed in mice backcrossed onto an
inbred genetic strain such as C57/BL6 strain.
Finally, the challenge to elucidate the role of FX in development remains.
Though a system [i.e. FX(-/F)] is in place to study the developmental role of FX,
much remains to be learned.  This work would entail the examination at
different developmental time points of a large number of FX(-/-) embryos born
to low FX(-/F) mothers and their comparison to FX(-/-) embryos born to FX(+/-)
mothers with a much higher FX activity.  This work would also involve a detailed
examination of vasculature development in the yolk sacs as well as in the
embryos themselves.  One interesting experiment to pursue is to attempt
rescue of FX knock-out mice through yolk sac-specific expression of FX.  In
other words, can the embryonic phenotype of FX knock-out mice as exemplified
by the absence of yolk sac vasculature and re-absorption of embryos be
rescued by restoration of FX expression in the yolk sac.  This rescue would
provide evidence for FX function in vasculature development and/or
maintenance and the phenotypic characteristics of the FX(-/-) embryos from the
rescued yolk sacs can then be evaluated.   Although the exact cause of
embryonic lethality in FX knock-out mice remains to be defined, this study and
future studies outlined above will provide a better understanding of an elusive
yet essential role of FX in development.
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